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INTRODUCTION  
 
Severe cutaneous adverse events are one of the dermatological emergencies. The clinical presentation 
of cutaneous adverse drug reactions (CADRs) could range from self-limiting maculopapular exanthema 
(MPE) to life threatening toxic epidermal necrolysis (TEN). Fortunately 90% of these are benign 
maculopapular eruptions which subside within a few days of discontinuation of the drug (1), without 
any significant long term complications. However, approximately 1: 1000 hospitalized patients with 
cutaneous adverse drug reactions also manifest systemic features such as fever, lymphadenopathy and 
visceral involvement. This accounts for a significant burden on health care costs.  
 
There is a lack of conclusive diagnostic tests available for confirming the cutaneous adverse drug 
reactions (CADRs). Diagnosis is often clinical. There are many criteria which have been proposed for 
the diagnosis of severe cutaneous adverse reactions (SCARs). The dilemma arises when a SCAR 
presents with a rash reminiscent of a maculopapular exanthema (MPE) in the early phase of the illness. 
Systemic involvement may not be apparent at this stage. In the absence of adequate follow up, 
misdiagnosing the rash as an ordinary drug induced skin reaction (ODSR) can have grave 
consequences. 
 
In this setting, identification of biochemical markers that can promptly assess the potential risk of a 
rash progressing to a SCAR, looks promising. Granulysin is a cytolytic granule protein produced by 
cytolytic T cells and natural killer cells which plays a crucial role in immunity (2). It has recently 
garnered attention due to its role in the pathogenesis of Stevens – Johnson syndrome and Toxic 
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epidermal necrolysis. However, there are few studies that have studied its role in other CADRs. 
Despite extensive literature search, we did not find any Indian studies that have studied the role of 
granulysin in cutaneous adverse drug reactions. 
 
In this proposed study, we aim to measure the serum granulysin in patients with different CADRs 
including SCARs and non-severe reactions such as MPE, and correlate it with the clinical severity of 
the disease. We hope to identify the utility of serum granulysin as a rapid diagnostic test for CADRs 
and as a novel therapeutic target for the management of severe adverse reactions. 
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      AIMS AND OBJECTIVES 
 
1. To measure the serum levels of granulysin and study its relationship with disease severity in  
patients with drug induced exanthemas and severe cutaneous adverse reactions. 
2. To study the clinical and cutaneous profile of patients with drug induced exanthemas and severe 
cutaneous adverse reactions. 
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REVIEW OF LITERATURE 
 
I.INTRODUCTION 
 
Edwards and Aronson defined adverse drug reaction as “an appreciably harmful or unpleasant reaction, 
resulting from an intervention related to the use of a medicinal product, which predicts hazard from 
future administration and warrants prevention or specific treatment, or alteration of the dose regimen, 
or withdrawal of the product”(3).  
 
A hospital- based surveillance by the ‘WHO International Programme for Adverse Reaction 
Monitoring’ identified skin as the most frequently affected organ in adverse drug reactions (4,5). They 
account for 3-6% of all hospital admissions and 5-9%  of hospital admission costs (6). Therefore they 
are a big burden on the public healthcare system, especially in low income countries. Studies on large 
cohorts of hospitalized patients have estimated the incidence of cutaneous adverse reactions to be 
approximately 2% - 3% (7–9). The frequency of cutaneous adverse reaction to specific drugs vary from 
1% to 10% (1,5). While most drug related adverse events are maculopapular exanthema (MPE) 
(7,10,11) that closely mimic viral illnesses, some of the more severe adverse drug reactions can be 
fatal. 
 
II.CLASSIFICATION OF ADVERSE DRUG REACTIONS BASED ON PATHOGENESIS 
 
Adverse drug reactions can be broadly classified as : 
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1. Non- immunologic response 
2. Immunologic response  
The non-immunologically mediated reactions constitute 80-90% of the adverse drug reactions (ADRs). 
They are usually dose dependent and predictable. For instance, diarrhea after ingestion of antibiotics 
and mucositis with chemotherapeutic agents or hepatotoxicity with methotrexate (12,13). They are 
related to the pharmacological activity of the drug. 
 
In contrast, the immunologically mediated reactions are non dose-dependent and unpredictable. 
Approximately 90% of immunologically mediated reactions are maculopapular exanthema (14), but 
around 1 in 1000 hospitalized patients with adverse drug reactions are estimated to develop severe 
reactions (1). They result from a delayed type IV hypersensitivity response to the drug (fig 1). These 
can develop virtually with any drug, but few groups of drugs are more notorious for causing 
immunologically mediated drug reactions.  
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Figure 1- Revised Gell and Coombs classification of hypersensitivity reactions 
(Adapted from Pichler WJ. Drug hypersensitivity : classification and relationship to T-cell activation) 
 
It has been noted that maculopapular or morbilliform eruptions usually occur 9 ± 5 days after initiation 
of the drug, whereas most severe reactions have a longer latent period - 14 ± 7 days for Stevens - 
Johnson syndrome/ Toxic epidermal necrolysis (SJS/TEN) and 28 ± 14 days for drug reaction with 
eosinophilia and systemic symptoms (DRESS) (15). However, a rechallenge with the same drug 
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induces recurrences sooner. This suggests that the drug reaction is mediated by sensitization and a 
specific immunological memory rather than a direct toxic effect (15). 
Acute generalized exanthematous pustulosis (AGEP) and fixed drug eruptions (FDE) manifest within 
1-3 days. This is hypothesized to be due to recall phenomenon, secondary to an overt or latent exposure 
to the offending drug (15). 
 
III.SEVERE CUTANEOUS ADVERSE REACTIONS 
 
The World Health Organization defines a severe cutaneous adverse reaction as one ‘that requires 
hospitalization or prolongation of the current hospital admission, causes significant or persistent 
disability and puts life in danger or causes death’(3). A meta-analysis of prospective studies conducted 
in the United States of America showed that 6.7 % of drug reactions were SCARs (16) with a fatality 
rate of 0.32%. Severe cutaneous adverse reactions are a group of potentially life threatening drug-
induced systemic illnesses that occur as a result of complex patho-mechanisms and genetic 
predisposition. 
Severe cutaneous adverse reactions include the following entities : 
1. Stevens-Johnson syndrome (SJS) – Toxic epidermal necrolysis (TEN) spectrum 
2. Drug reaction with eosinophilia and systemic symptoms (DRESS)  
3. Acute generalised exanthematous pustulosis (AGEP) 
 
 While most maculopapular exanthemas and urticaria are secondary to antibiotics, severe cutaneous 
adverse reactions are usually secondary to drugs such as anticonvulsants and allopurinol (17). They can 
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also result in long term sequelae, thus affecting the quality of life of the surviving patients. It is of 
utmost importance to identify the offending drug and withhold it as early as possible, as this affects the 
outcome of the patient.  
 
1.STEVENS - JOHNSON SYNDROME / TOXIC EPIDERMAL NECROLYSIS 
 
In 1922, Stevens and Johnson used the term ‘Stevens – Johnson syndrome’ to describe the clinical 
syndrome of fever with a disseminated erythematous macular rash with a necrotic center, severe 
stomatitis and conjunctival involvement in two children. Later, Lyell coined the term ‘Toxic Epidermal 
Necrolysis’ to describe chafed-looking skin lesions in four patients, which he believed to be toxin-
mediated (18). ‘Necrolysis’ referred to the histopathological finding of epidermal necrosis in this 
syndrome. He subsequently identified a higher incidence of the above skin changes in patients who 
were on sulfonamides, antiepileptic agents and pyrozolones.  
 
It is now well known that SJS and TEN belong to a spectrum of disorders which only differ by the area 
of skin detachment. Stevens - Johnson syndrome presents with epidermal detachment involving less 
than 10% of the body surface area, whereas TEN refers to the most severe form with detachment of 
more than 30%. The intermediate variant is called SJS-TEN overlap. Erythema multiforme major and 
SJS were historically considered to belong to the same spectrum (19), but are now regarded as being 
clinically and aetiologically distinct (20). 
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1.1 Epidemiology of SJS/TEN : The annual incidence of SJS and TEN is estimated to be 1.2-6 cases 
per million population and 0.4-2 cases per million population respectively (21). However, actual 
numbers vary based on a number of factors such as age, gender, ethnicity, and prescription trends. 
Medications are responsible for around 80% of TEN and 50% of SJS cases (13).  The drugs 
commonly implicated in SJS/TEN are shown in table 1. The estimated mortality rates are 
approximately 5% for SJS and between 30 to 50% for TEN (22).  
 
Table 1 - Drugs commonly implicated in SJS/TEN 
 
Antibiotics 
 
Penicillins 
Cephalosporins 
Fluroquinolones 
Sulfa drugs 
Antimalarials 
NSAIDs 
 
Paracetamol 
Ibuprofen 
Nimesulide 
Mefenemic acid 
Antiepileptics 
 
Phenytoin 
carbamazepine 
Others 
 
ART 
Alternative medicines 
 
 
Adapted from Sethuraman et al (23) 
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1.2 Pathogenesis of SJS/TEN :  
Many HLA haplotypes such as HLA-B*1502, HLA-B*5801and HLA-B*5701  have been 
demonstrated to have susceptibility to develop toxic epidermal necrolysis after the administration of 
carbamazepine, allopurinol and abacavir respectively among Han Chinese population (24,25). 
Literature indicates that HLA-DQB1*0601 is associated with ocular complications in SJS in Caucasian 
patients (26). Yet another study indicates that HLA B12 is expressed in patients with TEN (27). Thus, 
HLA typing in patients among the at-risk ethnic groups plays a major role in prevention of CADRs. 
 
The widely accepted theory for pathogenesis of SJS/TEN states that in response to the drug or its 
metabolites, there is a cutaneous recruitment of antigen-primed CD8+ cytotoxic T lymphocytes (CTLs) 
and CD56+ natural killer cells (NK cells), directed against the keratinocytes in a major 
histocompatibility class (MHC) I - restricted manner (28,29). This keratinocyte apoptosis is mediated 
by granulysin, perforin and granzyme B which are present in the granules within CTLs and NK cells  
(30). It is noteworthy that these molecules are elevated in the blister fluid in SJS/TEN. Granulysin is 
exocytosed along with perforins which facilitates its entry into the keratinocyte. Thereafter it damages 
the cell membrane and disrupts the mitochondrial transmembrane potential and causes disseminated 
keratinocyte death (fig 3) (30). 
 
The alternate theory proposes that Fas - Fas Ligand signaling pathway produces caspase 8 activation, 
which induces cell apoptosis (31,32). This mechanism is induced by cytokines and other soluble factors 
such as tumour necrosis factor α (TNF-α), Interferon γ (IFN-γ) , Interleukin 8 (IL-8) and nitric oxide 
(33).  
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Rechallenge with an offending drug typically shortens the incubation period and produces more severe 
clinical manifestations (15). Thus, educating the patient on the need for avoidance of re-exposure to the 
drug is crucial. 
 
1.3 Clinical features of SJS/TEN : 
After the maiden exposure to the drug, the skin and systemic symptoms commence within 7-21 days 
(34). There is a prodrome of fever, myalgia, arthralgia, anorexia, rhinorrhea and a pricking sensation of 
mucocutaneous surfaces. In the initial stage, the skin manifestation are composed of pruritic 
maculopapular, urticarial, petechial or purpuric rashes. Lesions are bilaterally symmetrical and 
generally start on the trunk, followed by involvement of the head and neck and proximal aspects of 
extremities. Distal extremities, palms and soles are rarely involved (34). These may evolve into target-
like lesions, which may rapidly develop into vesicles and bullae. This results from epidermal 
keratinocyte necrosis and subsequent sub-epidermal detachment. Nikolsky and Asboe-Hansen signs are 
positive. The denuded dermis appears shiny and erythematous with pinpoint bleeding spots. On an 
average, this evolution of symptoms occurs in 6-9 days (35). 
 
Mucosal involvement is seen in 90% patients with SJS/TEN and they tend to appear early in the course 
of the disease. This is predictive of a higher risk of progression of SJS to TEN (1). Ocular mucosal 
involvement, ranging from hyperemia to corneal rupture, is seen in 85% and genital involvement is 
seen in 40-60% patients. All three mucosae may be involved in up to 50% patients (34). 
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Often, SJS/TEN are complicated by end organ damage affecting the renal, pulmonary, gastrointestinal 
and cardiovascular systems. Renal damage occurs as a consequence of hypovolemia, decreased cardiac 
output and cytokine induced nephrotoxicity. It may present as dyselectrolemia, pre-renal 
hyperazotemia, renal tubular necrosis and acute renal failure (36). Bronchiolitis obliterans and diffuse 
interstitial pneumonitis may develop and therefore it is paramount to closely monitor for the same even 
if initial chest radiographs are normal. 
 
1.4 Scoring system : 
Severity of TEN can be assessed by SCORTEN scale (37), which is an aggregate score based on seven 
independent parameters that can adversely affect the outcome in the patient (table 2). In addition, it is a 
useful tool for prognosis.  
Table 2 - SCORTEN scale for assessment of severity of TEN 
S.no Variable  Values  Score  
1 Age  ≥ 40 years 1 
2 Heart rate ≥ 120 bpm 1 
3 Malignancy   1 
4 Initial 
epidermolysis  
≥ 10% BSA  1 
5 Serum urea ≥ 10 mmol/L 1 
6 Serum bicarbonate < 20 mmol/L 1 
7 Serum glucose ≥ 14 mmol/L 1 
Adapted from Bastuji – Garin et al (37) 
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SCORTEN score is calculated within 24 hours of admission and repeated on the third day. The risk of 
mortality increases with SCORTEN score, and the predictive value is best when calculated on the third 
day of admission (38). Mortality prediction based on the SCORTEN score is represented in table 3. 
 
Table 3 – Mortality prediction based on SCORTEN score 
 
SCORTEN score Percentage of mortality 
1 3.2 % 
2 12.1 % 
3 35.8 % 
4 58.5 % 
≥ 5 90% 
 
1.5 Management of SJS/TEN: 
Management of SJS/TEN is largely supportive. This includes discontinuation of the culprit drug, 
admission in an intensive care facility for fluid and electrolyte management, thermoregulation, 
adequate nutrition, analgesia and prevention of secondary infections. The main cause of mortality is 
secondary infection leading to sepsis. Therefore it is essential to provide reverse barrier nursing and 
antimicrobial therapy as deemed fit by the clinician. Re-epithelialization occurs by the migration of 
keratinocytes from the follicular reserves and recovery occurs within 3 weeks (34).  
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The cutaneous sequelae of SJS/ TEN include dyspigmentation of skin, alopecia, hypohidrosis or 
anhidrosis, scarring and nail changes, to name a few. More significantly, these patients may also 
develop mucosal changes, most common of which are ocular changes like chronic conjunctivitis, 
pseudomembrane formation and cataracts.  Ectropion, corneal scarring and subsequent loss of vision 
are dreaded complications which need to be prevented by proactive therapy during the acute phase of 
the disease. Long term complications of the respiratory tract may lead to chronic bronchitis, 
bronchiectasis and bronchiolitis obliterans. Similarly, involvement of the gastrointestinal tract and 
genitourinary tract may lead to mucosal strictures. Hypopharyngeal stenosis, dental hypoplasia, 
glomerulonephritis and idiopathic thrombocytopenic purpura have also been described. Finkelstein et 
al reported relapse of SJS/TEN in 7.2% patients with a mean duration of 315 days between the 
episodes (39). The cause of the relapse was proposed to be cross-reactivity with drugs with a similar 
chemical structure, and genetic susceptibility.  
 
There are contradicting schools of thought regarding the use of systemic agents in the acute phase of 
the disease. Till the early 1990s, systemic steroids were the accepted standard of treatment for 
SJS/TEN. However, since then it has been shown to increase the risk of complications such as sepsis 
and gastrointestinal bleeding (40). High dose pulse steroid therapy has been proposed as an alternative 
to reduce these complications. Steroids suppress the release of cytokines and inhibits T cell and Fas 
ligand mediated cell death. 
 
Many other systemic agents have been tried in the treatment of SJS/TEN. Cyclosporine inhibits CTLs 
by suppressing IL-2 production and thereby decreases the levels of granulysin (41). Intravenous 
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immunoglobulin was successfully used for a series of 10 patients with TEN in 1998 (42). It is thought 
to inhibit the Fas ligand pathway mediated keratinocyte apoptosis. Other regimes that have been used 
for the management of SJS/TEN are corticosteroids or infliximab in combination with Intravenous 
immunoglobulin (IVIG). N-acetylcysteine is a cysteine derivative with antioxidant properties and a 
capacity to inhibit TNF-α and IL1β. In addition, anti-TNF α blockers including biologics, 
pentoxiphylline and plasmapheresis have been used for treatment of SJS/TEN. 
 
2.DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) 
 
The term ‘Drug reaction with eosinophilia and systemic symptoms’ to describe the syndrome of a 
cutaneous adverse reaction with lymphadenopathy, haematological derangements and systemic features 
was introduced by Bocquet et al in 1996 (43). Prior to this, several other terminologies such as 
‘hypersensitivity syndrome’, ‘drug induced delayed multi-organ hypersensitivity syndrome’, ‘drug 
induced hypersensitivity syndrome’, ‘anticonvulsant hypersensitivity syndrome’ and ‘febrile 
mucocutaneous syndrome’ were variably used to describe this constellation of clinical features. There 
are a limited number of drugs suspected to cause DRESS syndrome. The drugs most commonly 
implicated are anticonvulsants, dapsone, allopurinol, minocycline, sulfasalazine and abacavir (44,45).  
 
Another characteristic feature of DRESS is the delay in onset of symptoms. The time duration between 
the initiation of the drug and the first cutaneous manifestation may range from 3-8 weeks (45). This 
presents a diagnostic challenge unless the index of suspicion is high. Other severe cutaneous adverse 
reactions have a shorter latent period and symptoms resolve more rapidly (46). Yet another factor 
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which compounds this difficulty in diagnosis is the clinical similarity of DRESS and infectious 
mononucleosis like syndrome (47).  Infection with human immunodeficiency virus, Hepatitis A virus, 
Hepatitis B virus and Influenza virus may also mimic DRESS syndrome (46).  
 
2.1 Pathogenesis of DRESS syndrome : 
The exact mechanism of DRESS is not fully understood, but three main components are thought to be 
involved. 
1. Abnormalities in metabolic pathways resulting in the accumulation of reactive metabolites (such 
as a deficiency or abnormality in epoxide hydroxylase, an enzyme that detoxifies the metabolites 
of aromatic amine anticonvulsants) ; 
2. Associated sequential reactivation of herpesvirus family members ; 
3. Ethnic predisposition in people with certain HLA alleles (immune response) (15,30,31,36). 
Saito et al proposed that granulysin is secreted against the virus infected cells in DRESS. This 
hypothesis explains the prolonged elevation of serum granulysin in DRESS, which coincides with the 
reactivation of herpes viruses (47). 
 
2.2 Clinical features of DRESS syndrome : 
Cutaneous changes are composed of urticated or infiltrated papules, and less commonly, vesiculo-
bullous lesions, pustules or purpura. The skin lesions may further progress to erythroderma (48). The 
cutaneous eruption may also mimic AGEP or EMM. However, a particular morphology of rash is not 
required for the diagnosis as it is based on the characteristic clinical course, organ involvement and 
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human herpes virus (HHV-6) reactivation. DRESS syndrome with skin features similar to SJS/TEN 
have been reported, in which the diagnostic criteria of DRESS syndrome is fulfilled but patients in 
addition exhibit epidermal detachment and mucosal erosions characteristic of SJS/TEN. Patients with 
DRESS syndrome are typically febrile with lymphadenopathy, leukocytosis, peripheral eosinophilia 
and deranged liver function tests. Facial or periorbital oedema may be present (49), in addition to 
interstitial inflammation of the liver or kidneys (44,45).  
 
There is a chronic clinical course in DRESS as compared to the other SCARs due to the high frequency 
of relapse. There may be reactivation of HHV-6 two to three weeks after the onset of the symptoms, 
which presents as fever and hepatitis. There have been reports of reactivation of other herpes viruses 
including HHV-7, cytomegalovirus (CMV) and Epstein Barr virus (EBV). Among these, CMV 
reactivation is associated with recurrent transient fever, cutaneous eruption and systemic complications 
such as myocarditis, pneumonitis or gastrointestinal bleeding (48). Epstein Barr virus and HHV-7 
reactivation are thought to have no clinical implications. It has been postulated that there is a transient 
drug-induced hypogammaglobulinemia during the acute phase of DRESS syndrome which enables 
viral reactivation (50). The estimated mortality rate of DRESS is approximately 10%. The most 
common cause of death is acute liver failure (51,52). 
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The chronology of events in DRESS is depicted in the figure below (fig 2). 
 
Figure 2 – Chronology of events in DRESS 
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2.3 HLA associations in DRESS syndrome : 
The extent of skin involvement varies from patient to patient and this is probably a reflection of genetic 
susceptibilities and environmental factors. For instance, it has been demonstrated that there is a strong 
association between HLA-B*5801 and allopurinol induced DRESS and SJS in the Han Chinese 
population(24).  
 
2.4 Criteria for DRESS syndrome :  
The RegiSCAR criteria was formulated to aid in the diagnosis of DRESS syndrome in view of its 
multitude of presentations (53) – Annexure 6. 
Another diagnostic criteria for Drug induced hypersensitivity syndrome (DIHS) in use is the Japanese 
consensus group criteria, which includes the following : 
1. Maculopapular rash developing after 3 weeks of initiation of the suspected drug 
2. Symptoms persisting beyond 2 weeks of stopping the drug 
3. Fever >38 degree Celsius 
4. Liver abnormalities (ALT>100U/L) or other organ involvement 
5. Leukocyte abnormalities  
a) leukocytosis > 11000/ml 
b) atypical lymphocytosis >5% 
c) eosinophilia > 1500/ml 
6. Lymphadenopathy 
7. Human herpes virus 6 reactivation 
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The diagnosis is confirmed by the presence of all 7 of the above criteria (typical DIHS) or the first 5 of 
the 7 criteria (atypical DIHS). DIHS is believed to be a subset of DRESS which is more severe and 
associated with HHV-6 reactivation (48). 
 
It is a daunting task to determine the drug responsible for the adverse reaction, especially in patients 
with a history of polypharmacy. In DRESS syndrome, patch testing and lymphocyte transformation 
testing  (LTT) have been used for this purpose with reasonable success (46).  
 
2.5 Differential diagnosis :  
Differentials for DRESS syndrome should include viral exanthema, vasculitides and other 
haematological and lymphocytic conditions. Among vasculitides, polyarteritis nodosa (PAN), 
granulomatous polyangiitis (GPA), eosinophilic granulomatous polyangiitis (EGPA), systemic lupus 
erythematosus (SLE), Kawasaki disease and Still’s disease are known to cause skin manifestations 
similar to DRESS syndrome. Angioimmunoblastic lymphadenopathy (a subtype of peripheral T cell 
lymphoma), lymphoma, pseudolymphoma and idiopathic hypereosinophilic syndrome are the other 
diseases to be considered when evaluating a patient with suspected DRESS syndrome (46).  
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2.6 Management of DRESS syndrome : 
Once the clinical diagnosis of drug reaction with eosinophilia and systemic symptoms is suspected, the 
offending drug has to be stopped immediately to prevent further compromise of the visceral organs. 
Patients with DRESS syndrome complicated by exfoliative dermatitis should be admitted in an 
intensive care or burns unit for further supportive care and there should be a low threshold for initiation 
of systemic steroids (46).  It is recommended that systemic steroids be gradually tapered and stopped, 
unlike in SJS/TEN with close monitoring of haematological, renal and hepatic parameters.  
 
3.ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS  
 
In 1968, Baker and Ryan described a group of patients with a pustular dermatosis who had an acute 
course and resolution, absence of history of psoriasis and in whom the episodes did not recur (54). 
They used the term ‘exanthematic pustular psoriasis’ to describe this constellation of features and 
suspected the condition to be triggered by drugs or infection. Meanwhile, the terms ‘toxic 
pustuloderma’ (55) and ‘pustular drug rash’ (56) were used to describe patients with a similar 
symptomatology. The current term was introduced by Beylot et al in 1980.  
 
3.1Clinical features of AGEP : 
Acute generalised exanthematous pustulosis is a cutaneous adverse reaction characterized by sheets of 
sterile pinpoint non-follicular pustules on an erythematous oedematous base, with a predilection for the 
face and flexural areas (57–59). The diagnosis is largely uncomplicated due to the distinct morphology 
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of the skin lesions. The latent period is short and ranges between two to five days. Confluent pustular 
lesions may show epidermal detachment mimicking TEN, however, this is rare (57). Mucosal 
involvement is uncommon though cheilitis may be seen in around 20% of the patients (12,57). The 
pustules typically resolve in 4-10 days with a characteristic pinpoint desquamation.  
 
Haematological abnormalities that may accompany the skin changes are leukocytosis, neutrophilia, and 
less commonly, eosinophilia (59). Involvement of the bone marrow may result in agranulocytosis. 
Systemic features are rarer than with other SCARs though pulmonary, renal and hepatic involvement 
have been described (57). The rate of mortality for patients with AGEP is less than 5% (12). Mortality 
in AGEP is strongly associated with multiple comorbidities and secondary infection. 
 
3.2 Pathogenesis of AGEP :  
The drug-specific T lymphocytes migrate to the epidermis and induce keratinocyte apoptosis, mediated 
by Fas ligand, perforin and granzyme B, in a manner similar to the pathogenesis of SJS/TEN. 
Enhanced expression of IL-8 and IL-3 stimulates neutrophil migration, resulting in the formation of the 
characteristic pustules.  
More than 90% cases of AGEP are drug induced. The drugs commonly implicated in AGEP are 
antimicrobial agents such as penicillins, macrolides and quinolones, antimalarials, carbamazepine, 
paracetamol and terbinafine (12,57). The incidence of AGEP in patients on antiepileptics, sulfonamides 
and allopurinol is lower than the other SCARs (58).  
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3.3 Management of AGEP : 
The diagnosis in AGEP is clinical. Roujeau et al (59) proposed the criteria for identifying potential 
cases of AGEP. A more elaborate scoring system was proposed by Sideroff et al (57) (Annexure 7). 
Acute generalised exanthematous pustulosis is generally amenable to treatment with topical 
corticosteroids and oral antihistamines. Severe manifestations may prompt the usage of short course 
systemic steroids. 
 
IV.ORDINARY DRUG RELATED SKIN REACTIONS 
 
There are several non-severe cutaneous adverse drug reactions ranging from pigmentation to urticaria. 
The common immunologically mediated non severe cutaneous adverse drug reactions are : 
maculopapular exanthema, erythema multiforme major and fixed drug eruption.  
 
1.ERYTHEMA MULTIFORME MAJOR 
 
 
Historically, erythema multiforme was believed to be a spectrum of disorders, namely, EM major, EM 
minor, SJS and TEN (19). But now, it is considered as a distinct hypersensitive response to triggers like 
drugs and infections (20). Erythema multiforme is characterised by a symmetrically distributed 
polymorphous rash with a preponderance for distal extremities (60). The classical phenotype comprises 
of target lesions (erythema iris) which may progress to epidermal detachment or oedematous papules 
(erythema papulatum), and mucosal involvement. There may be associated epidermal detachment EM 
minor does not affect more than one mucosa, whereas EM major may affect two or more mucosae 
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(61,62). More than half the reported cases occur secondary to herpes simplex virus infections. The 
drugs commonly implicated in EM major are barbiturates, phenytoin, NSAIDs, sulfonamides and 
penicillins (60). 
 
2.MACULOPAPULAR EXANTHEMA 
 
Maculopapular exanthema are characterized by an erythematous maculopapular eruption which occurs 
within 15 days of ingestion of a drug (63). This may be associated with fever, but the general condition 
of the patient is preserved. Peripheral eosinophilia may be seen in the range of 700 – 1000 cells/ml. 
 
3.FIXED DRUG ERUPTION 
 
Fixed drug eruptions usually manifest within 21 days of ingestion of the offending drug. They present 
as a limited number of erythematous plaques, which resolve with often long lasting pigmentation. 
There may be vesiculation overlying these plaques. A rechallenge with the drug typically produces 
recurrence of lesions at the same site (63,64). 
 
V.DIAGNOSTIC CONSIDERATIONS IN CADRs 
 
There are no conclusive diagnostic tests for CADRs. However, various molecular, serological and 
immunohistochemical aids have been developed for accurate diagnosis and prognostication of 
cutaneous adverse reactions. 
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1. HISTOPATHOLOGY : 
 
1.1 SJS/TEN - Histopathological examination of the initial skin lesions of SJS/TEN show necrotic 
keratinocytes in the stratum basale with basal membrane vacoulization. Lymphocytic inflammatory 
infiltrate is accompanied by dermal eosinophilia. The later stages are characterized by subepidermal 
blistering. However, it has been reported that spongiosis, dermal oedema and eosinophilia are more 
common in SJS than in TEN (63). 
1.2 DRESS - In DRESS syndrome there is a predominantly perivascular lymphocytic infiltrate with a 
small fraction of cases showing pustules (63). The infiltrate may also be in a lichenoid or interstitial 
pattern (63). Spongiosis and exocytosis are frequently observed, but basal cell vacuolization and 
eosinophilia are less common (63,65). 
1.3 AGEP - Intracorneal, subcorneal and/ or intraepidermal pustules are seen in AGEP, with oedema of 
the papillary dermis which is often marked. There is a perivascular infiltrate composed mainly of 
neutrophils, and exocytosis of eosinophils. Vasculitis with few necrotic keratinocytes may be seen 
with an absence of epidermal detachment (57–59). These findings suggest a passive extrusion of 
neutrophils from the blood vessels in the upper dermis, which is then eliminated through the 
epidermis (66).  
1.4 MPE - Maculopapular exanthema display a combined pattern of spongiosis, dermal edema with 
eosinophilia and perivascular infiltrate. Interface dermatitis and basal cell vacuolization are usually 
less intense in MPE(63,67,68).  
1.5 FDE - The most common histopathological features noted in FDE are necrotic keratinocytes and 
basal cell vacuolization (63). 
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2. IMMUNOHISTOCHEMISTRY 
 
Immunohistochemical studies on skin biopsies by Chung et al demonstrated intense staining of 
granulysin around the detached epidermis in SJS/TEN, as opposed to a weak staining in MPE (30). In 
the skin samples of healthy controls, granulysin was undetectable. This finding was reproduced by 
Weinborn et al. They additionally showed that there is an intense staining of granulysin in the 
inflammatory infiltrate in DRESS (63). Shlapbach et al studied tissue samples of patients with MPE, 
AGEP, FDE and TEN and showed that there is granulysin expression by CTLs and NKp46+ cells but 
with a varying intensity. The infiltration of NKp46+ cells was particularly high at the dermo-epidermal 
junction in TEN (69).  
In yet another study by Cho et al, the expression of granulysin in tissue and serum were found to be 
paramount for distinguishing between generalized bullous FDE and SJS/TEN (70). There is also a 
higher expression of granulysin and perforin per CD8+ T cell in SJS/TEN than in EMM (71). Thus 
immunohistochemical studies on granulysin expression in tissue can be used to differentiate between 
phenotypically similar CADRs such as SJS and EMM, SJS/TEN and GBFDE and DRESS and MPE in 
the early phase of illness. 
 
3. SKIN TESTS 
 
3.1 Patch test : 
 A diluted formulation of the drug is topically applied to the skin and observed for a cutaneous 
response after a specified period of time. The drug-primed T cells will act as cytotoxic effector cells 
and recruit inflammatory mediators to the site, thus causing a localized reaction. The sensitivity and 
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specificity of the test cannot be accurately determined due to the lack of any standard tests against 
which it can be compared.  
The test results are also dependent on a number of factors such as the type of drug being tested, its 
concentration and the vehicle used. For instance, the test is most reliable for antiepileptic agents such 
as phenytoin and carbamazepine. It must be ideally planned 2-6 months after the symptoms of the acute 
reaction subside. A positive test is highly predictive of a cutaneous adverse reaction but a negative test 
does not exclude its possibility. It is particularly safe and useful for identifying the drug responsible in 
AGEP and FDE (72). 
3.2 Prick test  
 Prick test is performed on the volar aspect of the forearm with the drug and the excipient. The test is 
considered to be positive when a wheal of diameter > 3 mm and more than that of a control with 
normal saline is seen at the site after 20 minutes (73).  
3.3 Intradermal test 
 Intradermal testing is contraindicated in patients with a history of EMM, SJS or TEN. Serial dilutions 
of the suspected drug is injected intradermally and observed for a wheal and flare response. 
 
4. MOLECULAR TESTS 
 
4.1 Lymphocyte transformation test  
The lymphocyte transformation test is an in vitro procedure which measures the H-thymidine uptake by 
dividing T cells and is therefore an indirect measure of the activation of T cells in response to a 
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particular drug. The test is safe, reproducible, can simultaneously assess the T cell response to multiple 
drugs and can detect drug reactions via different immune-pathologic mechanisms. The sensitivity of 
the test is 60-70% and specificity is 85%. The sensitivity also depends on appropriately timing the test, 
i.e, 5-8 weeks after the onset of DRESS/DIHS. In contrast, the test can be done 1 week after the acute 
phase in SJS/TEN and maculopapular exanthema (74). 
 
4.2 Macrophage migration inhibition factor (MIF) test 
 Macrophage migration inhibition factor is a chemokine released by antigen-sensitized T cells and is            
therefore, a reflection of cell-mediated immunity and delayed hypersensitivity (72,75,76). In MIF test, 
the patient’s lymphocytes and guinea pig macrophages are incubated in serial dilutions of the suspected 
drug. The migration of macrophages in the presence and absence of the drug is used to calculate a 
migration index. A migration index of < 0.8 is considered as a positive test (76). The sensitivity and 
specificity for this test are 57% and 96% respectively (77). 
 
4.3 Mast cell degranulation (MCD) test  
This test measures the histamine released by mast cells after incubating with the suspected drug. It is a 
useful tool in evaluating type I hypersensitivity related CADRs (75). The sensitivity and specificity of 
this test have not been elucidated.  
The other in-vitro tests that have been used in identifying the causative drugs in CADRs include 
lymphocyte toxicity assay, radioallergosorbent test (RAST) and interferon-gamma release test (75). 
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5. DRUG RECHALLENGE TEST  
 
These are in vivo tests that comprises of re-introducing diluted forms of the suspected drugs in a serial 
manner. They include : 
5.1 Oral provocation test ; 
5.2 Substitution test. 
Rechallenging a CADR patient with the suspected drug involves considerable risk and is undertaken in 
a controlled setting. It is contraindicated in patients with a history of SCARs. 
 
6. SEROLOGICAL TESTS 
 
In recent times, granulysin has gained popularity as an easily measurable biochemical marker in tissue 
or serum of patients with CADRs. Another biochemical marker, High Mobility Group Box 1 Protein 
(HMGB1) is under study for its role in the pathogenesis of SJS/TEN. 
 
VI. ROLE OF GRANULYSIN IN CUTANEOUS ADVERSE REACTIONS  
 
Severe cutaneous adverse reactions such as SJS/TEN and DRESS may present in the early stages with 
subtle skin lesions that resemble maculopapular and viral exanthema (4,78,79). In this setting, 
serological markers that can help in identifying the patients likely to progress to SCARs would help in 
initiating appropriate treatment, thereby reducing the rate of mortality. 
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1.1 Biochemical aspects of granulysin : 
Granulysin is a multifunctional, cationic cytolytic granule protein released by human CTLs (CD8+ T 
cells) and natural killer (NK) cells and has broad antimicrobial and tumoricidal properties. It is also a 
chemoattractant and has pro-inflammatory properties. It belongs to the family of saposin-like lipid 
binding proteins and has two forms – a 15 kDa precursor and a 9 kDa effector form. The precursor 
form is constitutively secreted, can be measured in the serum and may reflect the host cell immunity 
(2). On the other hand, the 9 kDa form is released by a calcium dependent granule exocytosis pathway 
and not detected in the serum. 
The 9 kDa form has cytolytic activity against microbes and tumors, whereas the 15 kDa form is 
elevated in acute viral infections and GVHD. The 15 kDa form is generally believed to be non-
cytotoxic. However, Chung et al showed that at very high concentrations, the 15 kDa granulysin 
possesses a potent cytotoxicity similar to that of the 9 kDa form. Injecting purified 15 kDa granulysin 
into mouse skin caused epidermal and dermal necrosis similar to that seen in SJS/TEN (30).  
 
1.2 Granulysin and immunity :  
Granulysin has been shown to be elevated in a number of conditions such as acute viral infections, 
malignancy, transplantation, and cutaneous diseases such as psoriasis (80), acne (81), lichen planus 
(82) and folliculitis (83). It has also been identified as a useful marker for GVHD in allogenic stem cell 
transplant as its serum levels correlate with the clinical severity (84). Granulysin has a longer half- life 
as compared to other cytokines, and hence, it can be a useful marker of in-vivo cell mediated cytotoxic 
immune responses. 
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1.3 Granulysin in the pathogenesis of SJS/TEN : 
It has been established that CTLs and NK cells infiltrate the skin in SJS/TEN. But the disseminated 
keratinocyte apoptosis in SJS/TEN is out of proportion to this infiltration of inflammatory cells. It was 
thus suggested that there may be soluble mediators which are responsible for this massive keratinocyte 
cell death. Chung et al showed that the blister cells in SJS/TEN primarily comprises of CD8+ CTLs 
and CD56+ NKT cells, and that both the cells and blister fluid are cytotoxic. They measured secretory 
granulysin (15 kDa form) in the blister fluid and found it to be the most highly expressed cytotoxic 
molecule, responsible for the disseminated keratinocyte apoptosis that characterizes the syndrome. The 
9 kDa form of granulysin was not detectable. Granulysin titers were 2-4 fold higher than perforin, 
granzyme B and Fas ligand, and depleting the granulysin in the blister fluid reduced the cytotoxicity.  
Chung et al proposed that specific targeted therapy against granulysin may be useful in treatment of 
SJS/TEN. 
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Figure 3 – Mechanism of cell apoptosis by granulysin 
Adapted from saini et al (85) 
 
Fujita et al recently showed that serum granulysin is elevated 2-4 days before the development of 
mucocutaneous lesions of SJS/TEN (86). This makes it a useful marker to distinguish between early 
stage-SJS/TEN and ordinary drug induced exanthemas, especially if the test is done 2-4 days before the 
development of blisters. They demonstrated that granulysin concentration in the serum falls rapidly 
within 5 days after the development of mucocutaneous bullae and erosions. They also developed a 
rapid immunochromatographic assay which correlates well with the sandwich ELISA method for the 
detection of serum granulysin. This test has 80% sensitivity and 95.8% specificity. 
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1.4 Other biochemical markers : 
Another biochemical marker called High Mobility Group Box 1 Protein (HMGB1) has been found to 
be elevated in SJS/TEN(87). It is a 30 kDa non-histone nuclear protein and acts as a nuclear 
transcription regulator in the cells. It also activates the inflammatory cascade and thus can contribute to 
the pathogenesis of blistering in SJS/TEN. The sensitivity of HMBG1 assay is only 45.5%, but the 
advantage is that the HMBG1 levels are elevated for a longer time as compared to serum granulysin 
which normalizes within a few days of onset of bullae (87). 
 
In this proposed study, we intent to describe the clinical profile of patients with adverse reactions, 
measure the serum granulysin levels in CADRs and describe its correlation with the severity of the 
illness. Even though serum granulysin in few subsets of SCARs have been studied previously, to the 
best of our knowledge, there are no studies which have included all SCARs and compared the same 
with healthy controls and maculopapular exanthema.  
 
MATERIALS AND METHODS 
 
Study design: This study was performed as a single center, prospective, case-control study on patients 
with cutaneous adverse drug reactions. 
 
Study setting: The study was conducted at Christian Medical College, Vellore, Tamil Nadu. It is a 
tertiary care, 2858 bedded hospital, with an average out-patient attendance of 7000 per day. The 
Department of Dermatology, Venereology and Leprosy had an annual out-patient registration of 45839 
 
46 
 
in the year 2016 under Unit II. The study subjects were recruited from among the patients attending the 
Dermatology Unit II OPD and those referred from other departments as in-patient consultations. 
 
Study subjects : Adult patients with a suspected drug induced rash were eligible for inclusion in the 
study.  
Inclusion criteria :  
i) Patients with drug induced maculopapular exanthema, erythema multiforme major, generalised 
fixed drug eruption and severe cutaneous adverse drug reactions (SJS/TEN, DRESS,AGEP, drug 
induced erythroderma) 
ii)  Patients above 18 years of age and who were willing to participate in the study. 
Exclusion criteria :  
(i) Patients less than 18 years of age. 
(ii) Patients with viral exanthemas 
(iii) Patients with a history of malignancy/ transplant/ tuberculosis/ past or present history of 
inflammatory skin diseases. 
(iv) Patients not willing for participation in the study. 
 
 For the purposes of comparison, 20 age matched controls for SCARs were recruited. 
 Inclusion criteria for controls : 
(i) Healthy volunteers over 18 years of age. 
Exclusion criteria for controls: 
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(i) History of any preceding inflammatory skin disease/ malignancy/ tuberculosis/ transplant. 
 
Period of recruitment : Study subjects were recruited from November 2015 to May 2017 (19 
months). 
 
Recruitment : 
All patients with suspected drug induced exanthemas and severe cutaneous adverse reactions (based on  
clinical and biochemical examination) fulfilling the inclusion criteria and seen in Dermatology unit II  
OPD or as in-patient consultations were included in the study. Naranjo assessment (Annexure 5) was 
done  
for each patient at the time of first contact of the patient by the principal investigator. An informed 
consent  
was obtained from all the patients and controls (Annexure 3). Among the in-patients recruited for the  
study, if the patient was indisposed due to the illness to provide consent, it was obtained from the  
patient’s attendant. The nature of the study and the investigation being done were explained to the 
patients  
and their attendants.  
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Data collection : After obtaining the consent of the patient/ patient’s attendant, the required details of  
the patient, including demographic details, history of the illness, clinical examination findings and 
relevant investigations were documented in a clinical research form (Annexure 4).  
 
Demographic details :  The name, age, gender, occupation, hospital number and contact details of the  
patient were documented. 
 
History : A detailed history of the drugs ingested and the symptoms experienced by the patients were  
taken. These included : 
 Latent period – the duration between the ingestion of the drug and appearance of the first symptom 
 The number of days since the onset of the first symptom of the adverse drug reaction  
 The duration of the rash  
 Associated features like itching, burning sensation, mucosal involvement, swelling of face, hands  
and feet  
 Systemic symptoms such as fever, jaundice, cough, arthralgia and breathlessness \ 
 Drug details such as the possible causative drugs and their indication, duration of drug intake,  
concurrent drugs used  
 History of previous drug allergies and the type of previous CADR  
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Clinical examination : Vital signs comprising temperature, pulse rate, blood pressure and respiratory 
rate were noted. A thorough lymph node examination, including the number of sites were documented. 
A systemic examination was also performed on all the patients. 
 
Cutaneous examination : The following clinical parameters were described in the patients : 
 The presence of facial oedema  
 Morphology of the skin lesions - blanching erythema, macular, papular, maculopapular, 
purpuric, targetoid, vesiculobullous, pustular or erosions   
 The extent of the rash in terms of body surface area (BSA) as calculated by the “Rule of Nine”  
 The number of mucosae involved, along with a description of the mucosal lesions  
 Palmoplantar involvement  
 Associated nail or hair changes 
Photographs of the relevant skin lesions were taken. In addition, SCORTEN score was calculated in 
SJS/TEN patients.  
 
Investigations : Routine haematological evaluation included counts, platelets and haemoglobin, liver 
and renal function tests, and HIV ELISA.  An electrocardiogram, chest radiograph and urine eosinophil 
count were also done in patients with suspected visceral involvement.  
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Histopathological examination : Skin biopsy was performed on a case to case basis to rule out 
differentials like viral exanthems and connective tissue disorders. The biopsy was performed from the 
most representative skin lesion at the first assessment by the principal investigator. A skin punch of 
size 4 to 6 millimeters was used to do the biopsy and the specimen was transported to the department of 
Pathology in the routine skin fixative solution. The specimen was processed and then stained with 
eosin and hematoxylin stain. The slides were examined under light microscopy in the pathology 
laboratory by a senior pathologist. The following features in the specimens were noted – 
orthokeratosis, parakeratosis, necrotic keratinocytes, spongiosis, focal basal cell vacuolization, the type 
of inflammatory infiltrate and lymphocytic exocytosis.  
 
Diagnosis : 
The final diagnosis was made by the principal investigator and the guide on each included case after 
reviewing the history, clinical features, photographs and investigations.  
All CADRs were further classified as : 
 Maculopapular exanthema 
 Severe cutaneous adverse reactions 
 Erythema multiforme major 
 Generalised fixed drug eruption 
Severe cutaneous adverse reactions comprised of SJS/TEN spectrum, DRESS syndrome, drug induced 
erythroderma and AGEP.  
The diagnostic criteria used for each of these were as follows : 
 
51 
 
 
DRESS syndrome : RegiSCAR criteria and RegiSCAR scoring were used to define DRESS 
syndrome.  
RegiSCAR criteria comprises of the following essential criteria :  
1. Hospitalization  
2. Reaction suspected to be drug related  
3. Acute skin rash 
In addition, the patient has to have at least 3 of the following asterisked criteria. 
4. Fever *  
5. Enlarged lymph nodes *  
6. Involvement of at least one internal organ*  
7. Haematological abnormalities *  
 
Each of the parameters in RegiSCAR criteria were defined as follows : 
1) Rash refers to any skin eruption which had an erythematous component and /or macular/ papular 
component. 
2) Lymphadenopathy was present if at least 2 non-contiguous sites were involved and the size of 
lymph nodes was more than 1 cm. 
3) Fever was defined as a temperature above 100.4°F (38°C). 
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4) Transaminitis : Liver involvement was defined by the serum level of alanine aminotransferase or 
aspartate transferase greater than twice the upper limit of the normal values on at least one occasion ( 
>80U/L)  
5) Kidney involvement: Creatinine was considered abnormal if the serum level was more than 1.6 mg 
% 
6) Blood count abnormalities:  
 Absolute lymphocytes above 5000 /cubic mm (lymphocytosis) or below 1500/cubic mm 
(lymphopenia).  
 Absolute eosinophils above 700/ cubic mm or >10% was considered to be peripheral 
eosinophilia. 
 Platelets below 100,000/ cubic mm was considered to be thrombocytopenia. 
Further, RegiSCAR scoring was used to classify patients as no case, possible DRESS, probable DRESS 
or definite DRESS.  
RegiSCAR scoring for DRESS syndrome is outlined below. 
Table 4 - RegiSCAR scoring 
SCORE -1 0 1 2 
Fever > 38.5°C No/U yes   
Enlarged lymph nodes   No/U yes  
Eosinophilia 
Eosinophils  
 
Eosinophils if TC < 4000/ml 
 No/U  
700/ml-
1499/ml 
10 -
19.9% 
 
>1500/ml 
 
>20% 
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Atypical lymphocytes   No/U yes  
Skin involvement 
Extent of rash (% BSA) 
Skin rash suggestive of DRESS 
Biopsy suggestive of DRESS 
 
 
No 
No  
 
No/U 
U 
Yes/U 
 
>50% 
 
yes 
 
Organ involvement 
Liver 
Kidney 
Lung 
Muscle/heart 
Pancreas 
Other organs 
Resolution >15 days 
 
 
 
 
 
 
 
No/U 
 
No/U 
No/U 
No/U 
No/U 
No/U 
No/U 
Yes 
 
Yes 
Yes 
Yes 
Yes 
Yes 
yes 
 
Evaluation of other potential causes 
ANA 
Blood culture 
Serology of 
HAV/HBV/HCV/chlamydia/mycoplasma 
If none positive and 3 or more of the 
above negative 
 
  
 
 
 
 
yes 
  
      U – unknown/ unclassifiable 
(Final score <2 -  no case, 2 to 3 – possible case, 4 to 5 – probable case, >5 – definite case) 
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Maculopapular exanthema : The cases with an acute cutaneous eruption, not fulfilling the RegiSCAR 
criteria were classified as maculopapular exanthemas. 
SJS-TEN spectrum : The diagnosis was made on the basis of characteristic mucocutaneous findings, 
drug history and systemic symptomatology. Patients with purpuric, targetoid or atypical target lesions, 
vesiculobullous lesions or erosions with involvement of ≥ 2 mucosae, with a temporal relationship to a 
drug known to produce a severe cutaneous drug reaction were included in this group. Patients were 
further subclassified as SJS (BSA <10%), SJS-TEN overlap (BSA 10-30%) or TEN (BSA>30%) (88). 
AGEP : Roujeau criteria (59), as outlined below, was used for the diagnosis of AGEP. 
1. Several dozens of small, mostly non follicular pustules arising on a widespread oedematous 
erythema ; 
2. Characteristic histopathological features – spongiform intraepidermal and/or subcorneal 
pustules, edema or papillary dermis, vasculitis, tissue eosinophilia and necrotic keratinocytes ; 
3. Fever more than 38 degree Celsius ; 
4. Blood neutrophil count more than 7 x 109/ L (7000/ml) ; 
5. Acute evolution with spontaneous resolution of pustules within 15 days. 
 
Additionally, the AGEP validation score of the EuroSCAR study group (57) was used to score patients 
with AGEP (Annexure 7). 
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Erythema multiforme major : Patients who presented with predominantly acrally distributed target 
lesions or raised oedematous papules with involvement of one or more mucous membranes were 
clinically diagnosed to have EMM (89). 
Fixed Drug Eruption : A diagnosis of FDE was made in patients with dusky erythematous macules or 
plaques with a tendency to resolve with often long lasting post inflammatory pigmentation. Recurrence 
of lesions at the same sites on drug rechallenge and involvement of less than two mucosae were 
additional clues to diagnosis (90). 
Controls : Twenty age-matched healthy volunteers over the age of 18 years were recruited as controls. 
One control was recruited for each case with a SCAR. The controls were inducted from patients 
attending the Dermatology OPD for minor skin complaints such as melasma, skin tags and xanthelasma 
palpebrum. Demographic details were entered in the proforma. Individuals with a  history of previous 
skin disease/ malignancy/ transplant or any other recent illnesses were not included.  
 
 
Figure 4 - Algorithm for classification of the study subjects 
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Measurement of serum granulysin : A blood sample was obtained for the measurement of serum 
granulysin for all the study patients at initial presentation. Samples were collected in EDTA tubes and 
transported to the Department of Clinical biochemistry at Christian Medical College, Vellore, by the 
principal investigator for all study subjects. The serum was frozen and stored at -70 degree Celsius in 
the laboratory till the time of the assay. The granulsyin concentrations of the serum samples were 
measured with Biovendor RD191327200R Human Granulysin ELISA, a sandwich-enzyme linked 
immunosorbent assay. The sensitivity of this test is 0.03ng/ml and there is no cross-reactivity with pro-
saposin. 
Standards (recombinant protein based) and samples were incubated in micro-titration wells pre-coated 
with polyclonal anti-human granulysin antibody. After 60 minutes incubation followed by washing, 
biotin-labelled polyclonal anti-human granulysin antibody was added and incubated with the captured 
granulysin for 60 minutes. Streptavidin-HRP conjugate was added after washing the wells. After 30 
minutes of further incubation followed by washing, the remaining conjugate was allowed to react with 
the substrate solution, tetramethylbenzidine (TMB). Absorbance of the resulting yellow product was 
proportional to the concentration of granulysin in the sample. A standard curve was constructed by 
plotting absorbance values against granulysin concentrations of standards. The concentration of 
granulysin in the samples were determined using this standard curve. The test results were verified by a 
senior biochemist. 
Statistical analysis :  
Calculation of sample size :  
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Here the primary objective is to calculate the mean value of serum granulysin and its confidence 
interval. Previous studies have shown that the mean concentration ± standard deviation (SD) of serum 
granulysin among healthy individuals was 3.7 ± 3.2 ng/ml (2) and that among patients with drug 
exanthema was 3.5 ± 3.4 ng mL (3). The mean concentration ± standard deviation of severe drug 
reactions was 30.35 ± 9.91 ng/mL. Hence, the sample size for the three groups were calculated as 
follows : 
 
With expected mean (SD) for SCARs group as 30(10), maculopapular exanthema as 10(3) and healthy 
controls as 10(3), the minimum required number of samples to be studied are n=16 on each group. The 
formula used is  
 
Here alpha level is taken as 1% and power as 90%.  
 
Statistical methods : 
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The data entry was performed using Epidata software and analysis by using SPSS software. The 
independent sample t test was used for the comparison of two categories with normal variables. For 
variables without normal distribution, Mann- Whitney’s U test was used. The association between 2 
categorical variables was checked by the chi-square test and the graphical representation of the analysis 
was done with bar plot and error plot. The analysis was done by Ms.Tunny Sebastian, Department of 
Biostatistics, Christian Medical College, Vellore. 
 
IRB approval : This study was approved by the Institutional Review Board of Christian Medical 
College, Vellore, bearing IRB Min number 9674 on 20/10/2015 and was funded by the Fluid research 
grant of the institution (Annexure 1). 
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RESULTS 
 
Forty eight patients with cutaneous adverse drug reactions who fulfilled the inclusion criteria were 
recruited during the study period of November 2015 to May 2017 (19 months). Among this cohort, 22 
patients had drug induced maculopapular exanthema, 21 patients had severe cutaneous drug eruptions, 
4 patients had erythema multiforme major and 1 patient had generalised fixed drug eruption. Among 
the SCARs, we diagnosed 12 patients with SJS/TEN, 7 patients with DRESS syndrome and one patient 
each with drug induced erythroderma and AGEP. The seven patients who fulfilled the RegiSCAR 
criteria for DRESS were identified as possible (4 cases) and probable DRESS (3 cases) by RegiSCAR 
scoring. The patient with AGEP received a score of 11 on the AGEP validation score by EuroSCAR 
study group and was classified as a definite case. 
Twenty age matched healthy volunteers were also included as controls. 
 
1. DEMOGRAPHIC PROFILE :  
1.1 Age : 
Out of the 48 patients included in the study, 19 patients (40%) belonged to the age group of 18-40 
years and 22 patients (46%) belonged to the group of 40-60 years. Only a minority (7/48, 14%) of the 
included patients were aged over 60 years. The age distribution of the study population is shown in 
figure 5. The mean age was 44.4 ± 14.6 years. 
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Figure 5 - Age distribution of patients with CADRs 
 
1.2 Gender : 
Seventy one percent (34/ 48) patients with CADRs were women as against 29% (14/48) men (figure 
6). This shows a significant female preponderance with a male: female ratio of 0.41:1.  
 
Figure 6 - Gender distribution of patients with CADRs 
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Both the MPE group and SCARs group showed a female predominance with 15/22 patients (68.18%) 
in the MPE group and 16/21 patients (76.19%) in the SCARs group comprising of women. Erythema 
multiforme major group showed equal number of males (2/4) and females (2/4). Only 1 female patient 
was present in the fixed drug eruption group. The gender distribution among the different types of 
CADRs is represented in figure 7. 
 
Figure 7 - Gender distribution of different types of CADRs 
 
1.3 Place of origin 
Majority of the patients were from Tamil Nadu (33/48, 68.75%), followed by Andhra Pradesh (7/48, 
14.6%). Three patients each were from West Bengal and neighbouring countries like Bangladesh and 
Bhutan. One patient each hailed from Kerala and Orissa (figure 8). 
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Figure 8 - Place of origin of patients with CADRs 
 
2. CLINICAL PROFILE  
2.1 Presenting symptoms : 
The most common symptoms at presentation were fever with mucocutaneous involvement (19/48, 
39.6%), followed by fever with skin involvement (17/48, 35.4%) and cutaneous involvement alone 
(12/48, 25%) (figure 9). 
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Figure 9 - Presenting symptoms of patients with CADRs 
 
2.2 Latent period :  
 
The time period between the onset of drug intake and first symptom is shown in table 5.  
 
Table 5 – Latent period with the different CADRs 
 
                                                          Type of CADR 
Parameter AGEP SJS/TEN DRESS Erythroderma MPE FDE EMM 
Mean ± 
SD (days) 
1 12.5 ± 9.1 16.1 ± 
10.3 
27 8.4 ± 
7.2 
1 21 ± 
27.4 
 
The latent period in AGEP and FDE was 1 day, and in erythroderma, it was 27 days. Among the other 
CADRs, MPE had a shorter latent period  (8.4 ± 7.2 days) as compared to SJS/TEN (12.5 ± 9.1 days) 
and DRESS (16.1 ± 10.3 days). The EMM group had a mean latent period of 21 ± 27.36 days.  
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 2.3 Other symptoms in CADRs : 
Besides fever and rash, the most common symptoms in the study patients were oedema of the face, 
hands or feet, followed by cough, dyspnea, jaundice and arthritis respectively. The frequency of these 
symptoms in CADRs is shown in figure 10. 
 
 
Figure 10 - Symptoms in patients with CADRs 
 
In our study, we found that facial oedema was seen in 14 patients (29.2%) of the total patient 
population, (6 SCARs, 5 MPEs, 2 EMM and 1 FDE). In addition, a history of facial oedema was 
elicited in 3 patients (two patients with drug induced erythroderma and one patient with MPE). 
However, on examination, facial oedema had resolved in these patients. The prevalence of facial 
oedema in our study population is represented in table 6. 
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Table 6 - Prevalence of facial oedema among CADRs 
 
CADR Frequency Percentage 
MPE 5/22 22.7% 
SCAR 6/21 28.57% 
EMM 2/4 50% 
FDE 1/1 100% 
 
 
2.4 Day of presentation : 
Fifty eight percent of patients with CADRs presented within 5 days of onset of complaints, whereas 
27% presented between 6-10 days and 15% after 10 days (figure 11). The median day of presentation 
in MPE was 4 days (IQR 2 – 7.75 days) and that in SCARs was 5 days (IQR 3 – 9.5 days). 
 
Figure 11 – Duration of onset of the rash 
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Majority of the men with CADRs (64%) presented within 5 days of onset of symptoms, 42.8% between 
6-10 days, and 7%  after 10 days of onset of symptoms. Among women, 55.9% presented early in the 
course of illness, i.e, within 5 days, 20.6% within 6-10 days and 17.6% after 10 days of onset of 
complaints (Table 7). 
 
Table 7 - Gender distribution vs day of onset of symptoms 
 
Number of days since the 
onset of complaints 
Male Female 
1-5 days 9 (64.3%) 19 (55.9%) 
6-10 days 6 (42.8%) 7 (20.6%) 
>10 days 1 (7%) 6 (17.6%) 
 
2.5 Comorbidities :  
Majority of the patients (n=45) had diseases other than the CADR. Diabetes was present in 10 patients 
(20.8%) and hypertension in 11 patients (22.9%).  
 
2.6 Alcohol consumption : Only 4 patients (8.3%) gave history of alcohol consumption. All of these 
patients were males. 
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3. DRUG DETAILS : 
3.1 Commonly implicated groups of drugs in CADRs : 
The most common group of drugs implicated in CADRs were antiepileptic drugs (35.4%) like 
phenytoin and carbamazepine, followed by antibiotics (18.8%). In 10 patients (20.8%), the causative 
drug was suggested to be either antibiotics or others (such as proton pump inhibitors, diuretics, sulfa 
drugs, anti-tuberculous drugs) by Naranjo algorithm. There were 2 patients (4.2%) who were on both 
antibiotics and antiepileptic drugs and the causative drug could not be accurately determined. The 
frequency of different groups of causative drugs is represented in table 8. 
 
Table 8 - Commonly implicated groups of drugs in CADRs 
 
 Total frequency MPE  SCARs EMM 
Antiepileptic 
agents 
17 (35.4%) 4 (23.5%) 10 (58.8%) 3 (17.64%) 
Antibiotics 9 (18.8%) 6 (66.67%) 2 (22.2%) 1 (11.1%) 
Others 7 (14.6%) 5 2  
Antiepileptics/ 
Antibiotics 
2 (4.2%) 1 1  
Antiepileptics/ 
others 
2 (4.2%)  2  
Antibiotics/ 
others 
10 (20.8%) 4 3  
Unknown 1 (2.1%) 1   
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Antiepileptic agents were implicated as causative agents in 47.6% SCARs whereas antibiotics were the 
common culprit drug group (27.3%) among MPE. This table is represented in figure 12. 
 
Figure 12 – Frequency of implicated drugs among patients with CADRs 
 
We identified one patient with a suspected MPE to siddha medicines taken for cold and eczema. 
Another patient who was treated with carbamazepine and rituximab for neuromyelitis optica spectrum 
disorder developed SJS. A diagnosis of carbamazepine induced SJS was considered in view of the 
temporal relationship to the drug and the typical morphology of skin lesions. As the patient had also 
received Rituximab just prior to developing the skin lesions, by Naranjo causality assessment, 
rituximab induced SJS was also considered as a possibility. Another case was an MPE to rabies 
vaccine/ immunoglobulin. 
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3.2 Past history of drug hypersensitivity : 
Five patients in the cohort had a past history of drug allergy. They had subsequently developed MPE 
(n=2), FDE (n=1), drug induced erythroderma (n=1) and AGEP (n=1). The patient with the generalised 
FDE had a past history of FDE to an unknown drug. The current episode also followed ingestion of an 
unknown drug over the counter. The patient with AGEP to penicillin reported a non-severe drug 
reaction previously to the same drug. The other 3 patients had a past history of drug hypersensitivity to 
drugs unrelated to the culprit drug in this study. 
 
4. RASH CHARACTERISTICS  
4.1 Morphology of the rash : 
The morphology of the skin lesions seen in the CADRs were varied. The most common skin lesions 
seen in the study cases were blanching erythema and papular skin lesions (17/48, 35.4% each), closely 
followed by target or atypical target lesions and erosions (16/48, 33.3% each). Fourteen patients had 
vesiculobullous skin lesions at the time of initial presentation, comprising of 29% of the total number 
of cases. Purpuric lesions, macules and pustules were seen in much less frequency. The additional skin 
findings were : flexural accentuation of the rash (n=3), scaling and desquamation and crusting (figure 
13). In 6 patients, the papules had an infiltrated appearance, in keeping with the findings expected in 
DRESS. 
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Figure 13 – Frequency of the different types of skin lesions in study patients 
 
A patient with MPE to chlorpromazine had a photo-distributed rash with maculopapular skin lesions on 
the exposed areas of the face and upper limbs. 
 
4.2 Body surface area involved in CADRs : 
Half of the study patients (n=24, 50%) had involvement of more than 30% BSA, while 25% had 10-
30% BSA and 25% had less than 10% BSA involved (figure 14). 
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Figure 14 – Body surface area involved in the study population 
 
The body surface area involvement in MPE and SCARs groups is shown in table 9. 
Table 9 – Body surface area involved in MPE and SCARs 
BSA MPE SCARs 
<10% 4 (18.2%) 5 (23.8%) 
10-30% 7 (31.8%) 4 (19.04%) 
>30% 11 (50%) 12 (57.1%) 
Total  n = 22 n = 21 
 
This table shows that 50% MPE cases and 57% SCARs had extensive skin involvement of more than 
30% body surface area. All 5 patients who had limited skin involvement in SCARs (<10%) were cases 
of SJS.  
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4.3 SCORTEN score for SJS/TEN : 
SCORTEN score was calculated for all our patients with SJS/TEN at admission and is represented in 
table 10. 
Table 10 – SCORTEN score for patients with SJS/TEN 
 
SCORTEN score SJS SJS-TEN overlap TEN 
1 2 1 0 
2 0 0 0 
3 1 1 1 
4 0 0 3 
≥ 5 0 0 1 
 
It can be seen that patients with TEN had a higher SCORTEN score than SJS and SJS-TEN overlap 
and thus, were at a higher risk of mortality. 
 
4.4 RegiSCAR score :  
RegiSCAR scoring was done for all patients with suspected DRESS. Based on this score, we stratified 
patients as having possible or probable DRESS and no case of DRESS (MPE). The mean RegiSCAR 
score for DRESS cases was 3.4 ± 0.97 and for MPE was -1.1 ± 1.7 (p value <0.001). 
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4.5 Palmoplantar involvement : 
Palmoplantar involvement was seen in 15 patients (15/48, 31.25%), with palmar lesions (n=13) being 
slightly more common than plantar lesions (n=11). The commonest morphological forms noted were 
atypical target lesions, blanching erythema, petechiae, purpura, collapsed bullae and scaling. 
Palmoplantar involvement was more common in SCARs than in MPE (9/21, 42.85% vs 3/22,13.6%). 
 
4.6 Facial involvement : 
Facial lesions were seen in 26 patients, comprising 54.2% of the cases included in the study. The MPE 
group showed facial involvement in 10 out of the 22 patients (45.5%). The most common 
morphological types of rash noted on the face in patients with MPE were facial oedema, blanching 
erythema, papules, macules and desquamation. Few patients also had features like perioral and 
periorbital papules and erythema of the ears. 
 
In the cohort of SJS/TEN, facial involvement was seen in 7 patients (58.3%). Atypical target lesions 
and facial oedema were the commonest findings, followed by purpura, vesiculobullous lesions and 
erosions. Majority of the patients with DRESS syndrome (n=3, 42.8%) had facial involvement, which 
consisted of facial oedema (n=2), erythema (n=1) and desquamation (n=2). Facial erythema was seen 
in the patient with drug induced erythroderma. Facial oedema was also seen in the patients with acute 
generalized exanthematous pustulosis and generalised fixed drug eruption. Two out of the four patients 
with erythema multiforme major had facial oedema. The distribution of facial rash in CADRs is shown 
in figure 15. 
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Figure 15 - Morphology of facial rash in CADRs 
 
4.7 Mucosal involvement :  
Conjunctival lesions were seen in12 patients (25% of the cases), oral lesions in 23 patients (47.9%) and 
genital involvement in 4 patients (8.3%). The frequency of at least one mucosal involvement was much 
higher in the SCARs group as compared to MPE group. Among the 22 patients with MPE, 3 patients 
had oral lesions (13.6%). One of these patients had cheilitis and another had discrete oral ulcers. A 
third patient had multiple oral ulcers which were probably secondary to neutropenia. Conjunctiva and 
genitalia were spared in MPE. All 4 patients with erythema multiforme major had oral mucosal lesions, 
2 patients (50%) had conjunctival lesions and one patient (25%) had genital lesions. The distribution of 
mucosal lesions in CADRs is represented in figure 16. 
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Figure 16 – Frequency of mucosal lesions in CADRs 
 
5. SYSTEMIC INVOLVEMENT 
The various laboratory parameters analyzed among the patients with CADRs showed haematological 
abnormalities and transaminitis to be the most frequent findings. Deranged renal function tests, 
pneumonitis and carditis were rarer. 
5.1 Lymphadenopathy :  
Significant lymph node enlargement was seen in 8 patients, with 4 patients having enlargement of 2 or 
more groups of lymph nodes. Only SCARs were associated with lymphadenopathy at more than two 
anatomical sites, whereas patients with MPE and generalized FDE had only involvement of a single 
group of nodes. The distribution of lymphadenopathy among CADRs is shown in figure 17.  
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Figure 17 – Lymphadenopathy in patients with CADRs 
 
5.2 Involvement of the respiratory system : 
Six out of the 48 patients (12.5%) had respiratory symptoms like cough and dyspnea, while abnormal 
chest radiograph findings were seen in 9 patients (18.75%). Three of these patients belonged to the 
MPE group and 5 patients were from the SCARs group (all 5 patients had SJS/TEN). Among the MPE 
patients, one patient had developed dyspnea following a surgical debridement for necrotizing fasciitis 
and her chest X-ray showed bilateral heterogenous lung infiltrates, which was probably not related to 
the CADR.  
Thus, respiratory findings were more common among SCARs as compared to MPE, but the difference 
was not statistically significant (p value 0.098). 
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5.3 Involvement of the gastrointestinal system :  
Gastrointestinal involvement was present only in 2 patients on clinical examination. One patient had 
hepatomegaly, while the other had ascites and abdominal distension. Transaminitis was seen in one 
third of the patients with SCARs (n=7/21, 33.3%) and only in one patient with MPE (table 11). Thus, 
transaminitis was significantly more common among SCARs than MPE (p value 0.021). 
 
5.4 Involvement of the renal system : 
Raised creatinine was seen in 3 patients each in the MPE and SCARs groups. The diagnosis in the 3 
SCARs patients was SJS/TEN. Out of the 3 MPE patients with raised creatinine, two suffered from 
chronic kidney disease and the third had multi-organ dysfunction. 
 
5.5 Involvement of the cardiovascular system : 
The patient with AGEP had cardiomegaly on chest radiograph. Electrocardiogram was not available for 
routine analysis among our study patients. Among the DRESS patients, ECG changes suggestive of 
mild ischemia was seen in one patient (n=1/7, 14.3%).  
 
5.6 Peripheral eosinophilia in CADRs : 
Eight patients included under MPE (36.4%) showed peripheral eosinophilia, with 4 patients having 
marked eosinophilia of >1000 eosinophils/ml. Thirty five percent of the patients with SCARs also 
showed eosinophilia (figure 18). 
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Figure 18 – Frequency of peripheral eosinophilia in CADRs 
 
5.7 Other haematological parameters : 
Lymphocytopenia was the most frequently encountered haematological abnormality and was present in 
33 of the 48 patients (68.75%). Lymphocytosis was not seen in any of our patients. Thrombocytopenia 
was more common in severe cutaneous adverse reactions as compared to the maculopapular 
exanthemas (28.6% vs 9.1%). 
The frequency of haematological, hepatic and renal abnormalities in CADRs is shown in table 11. 
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Table 11 - Abnormal laboratory parameters in CADRs 
 
          MPE                SCARs p value 
Lymphocytosis               0                0  
Lymphocytopenia             13   (59.1%)              16   (80%) 0.232 
Thrombocytopenia             2     (9.1%)               6 (28.6%) 0.132 
Transaminitis             1     (4.5%)               7 (33.3%) 0.021 
Raised creatinine             3    (13.6%)               3 (14.3%) 0.345 
Urine eosinophils             3    (13.6%)                0       
 
 
6. HISTOPATHOLOGICAL ANALYSIS 
Biopsy was not routinely done for all patients. It was done on a case to case basis to differentiate 
CADRs from connective tissue disorder or alternate diagnoses. 
Out of the 48 patients included, 50% (n=24) underwent biopsy, of which 12 patients were eventually 
classified as MPE, 10 patients were SCARs and 2 were erythema multiforme major. The most common 
histopathological feature seen in our study patients was dermal eosinophilic infiltrate (83.3%). This 
was followed by lymphocytic exocytosis and necrotic keratinocytes in 66.67% each and spongiosis in 
62.5%. Necrotic keratinocytes were seen in all the patients with SCARs whereas lymphocytic 
exocytosis and dermal eosinophils were seen in 90% patients with SCARs. 
The frequency and percentage of the most common histopathological findings among CADRs is 
represented in table 12. 
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Table 12 - Frequency of histopathological features in CADRs 
 
 Total frequency  
(n=24) 
MPE 
(n=12) 
SCARs 
(n=10) 
p value 
Spongiosis 15 (62.5%) 7 (58.3%) 7 (70%) 0.321 
Necrotic 
keratinocytes 
16 (66.67%) 5 (41.6%) 10 (100%) 0.01 
Basal cell 
vacoulization 
10 (41.6%) 3 (25%) 6 (60%) 0.192 
Lymphocytic 
exocytosis 
16 (66.67%) 6 (50%) 9 (90%) 0.045 
Dermal eosinophils 20 (83.3%) 10 (83.3%) 9 (90%) >0.99 
 
Focal basal cell vacoulization was seen in 71.4% patients with DRESS (n=5) and 60% patients with 
SJS/TEN (n=7). Lymphocytic exocytosis and necrotic keratinocytes were seen in all the patients with 
DRESS and SJS/TEN, and was significantly higher in SCARs than MPE (p value 0.045 and 0.01 
respectively). These findings were seen among 50% and 41.6% of MPE respectively. Spongiosis was 
seen in 58.3% patients with MPE (7 out of the 12 MPE patients). It was more common among the 
DRESS patients (100%, n=4, p value >0.99) but not statistically significant. Among patients with 
SJS/TEN, spongiosis was seen in 40% (2 out of 5 patients). 
 
  
 
81 
 
7. SERUM GRANULYSIN IN CADRs : 
Serum granulysin was measured in all the cases included in the study by the Biovendor 
RD191327200R Human Granulysin ELISA, a sandwich-enzyme linked immunosorbent assay. In 
addition, serum granulysin was also assessed in 20 age matched controls. 
The results of our study are outlined below. 
7.1 Serum granulysin titer in CADRs : 
The distribution of serum granulysin across the different types of drug rashes were skewed as seen in 
figure 19. Majority of the patients had serum granulysin values less than 1.00, except 2 patients in 
MPE group and one patient in SCARs group who had value >4.0. It was seen that the MPE patients 
with granulysin > 4 ng/ml (upper limit of detection by the test) had necrotizing soft tissue infections at 
the time of inclusion in the study. Hence they were excluded at the time of analysis of granulysin levels 
(fig 19).  
 The median value of serum granulysin in the different CADRs were : 
1. Maculopapular exanthema – 0.15 ng/ml (IQR 0.1075 – 0.2925) 
2. Severe cutaneous adverse reactions – 0.26 ng/ml (IQR 0.15 – 0.5) 
a. SJS/TEN – 0.275 ng/ml  
b. DRESS – 0.24 ng/ml  
c. AGEP – 0.1 ng/ml  
3. Drug induced erythroderma – 0.67 ng/ml 
4. Erythema multiforme major – 0.125 ng/ml (IQR 0.085 – 0.18) 
5. Generalised FDE – 0.1 ng/ml 
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6. Controls – 0.27 ng/ml (IQR 0.1325- 0.5225) 
 
Figure 19 - Distribution of serum granulysin in different CADRs 
 
There was no statistically significant difference in the serum granulysin titer between the MPE group 
and SCARs group or between the SCARs group and controls.  
An interesting finding in the study was that there was a significant difference in the serum granulysin 
between SJS/TEN and erythema multiforme major patients (p value – 0.042). 
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7.2 Steroid administration in patients with CADRs and serum granulysin levels : 
The serum granulysin levels were not influenced by the administration of systemic steroids in any of 
the groups. In fact, in the SCARs group, the patients who were on systemic steroids at the time of 
inclusion in the study had a higher median value of serum granulysin than the patients who were not on 
steroids (0.295 vs 0.24).  
 
7.3 Relationship between serum granulysin level and the time of presentation 
The serum granulysin titer did not appear to be dependent on the number of days since the onset of the 
rash in MPE, SJS/TEN or DRESS. The pattern of distribution of serum granulysin did not show 
significant elevation in patients who presented during the early phase of illness as compared to patients 
who presented in the late stages (figure 20). 
MPE 
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SJS/TEN 
Figure 20 – Serum granulysin vs day of initial presentation 
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CLINICAL PHOTOGRAPHS 
                     
 
 
 
 
a 
b 
c 
a – mucosal erosions in a patient with erythema 
multiforme major 
Target lesions on the forearm (b) and palm (c) of 
a patient with erythema multiforme major 
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d 
e 
f g 
d – epidermal detachment in a patient with SJS-TEN overlap 
e – erythematous papules and atypical target lesions on the distal aspect of arm of a patient 
with SJS 
f – diffuse cheilitis and atypical target lesions in a patient with SJS 
g – conjunctival suffusion in SJS 
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h i 
j 
h – facial and periorbital oedema in DRESS syndrome 
i – infiltrated papules and papulovesicles on the forearm of a patient with DRESS 
j – fine scaling and erythema in a patient with drug induced erythroderma 
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k 
l 
m 
k – cheilitis and facial oedema in a patient with 
maculopapular exanthema 
Photo-distributed rash secondary to 
chlorpromazine with a sharp demarcation at 
the covered sites (l,m) 
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n o 
Dull erythematous plaques (n) and overlying bulla (o) in a patient with generalized fixed drug 
eruption  
Erythematous oedematous plaques studded with pinpoint pustules on the abdomen (p). 
Pustules in the same patient resolving with characteristic desquamation (q) 
p q 
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DISCUSSION 
 
 
Serum granulysin is a molecule that has been under extensive study for its antibacterial and 
immunologic properties. The focus on serum granulysin as a marker for cutaneous adverse drug 
reactions has been recent, and there are few studies which have compared the levels of granulysin in 
the different types of CADRs (47,63). To the best of our knowledge, there are no Indian studies that 
have compared the serum granulysin levels in patients with drug induced MPE, SCARs, drug induced 
EMM and healthy controls. Our study aimed to explore the relationship between serum granulysin and 
the severity of CADRs and to study the clinical profile of patients with cutaneous adverse reactions. 
 
1. DEMOGRAPHIC PROFILE : 
A comparison of the demographic profile of the patients in this study with other Indian studies is 
tabulated below (table 13). It is noteworthy that the incidence of AGEP was low in all these studies, 
similar to our study. This could be because AGEP generally resolves spontaneously in a short period 
after discontinuation of the drug, rarely necessitating treatment. The relative paucity of SCARs in our 
patient group could be because of the exclusion of patients with CADRs to anti-tuberculous and anti-
retroviral therapy. 
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Table 13 - Comparison of demographic profile of patients with CADRs in different Indian studies 
 
Parameter 
 
Pudukadan 
et al (31) 
Sasidharanpillai 
et al (34) 
Sharma VK et 
al (35) 
Present study 
Country 
 
India India India India 
Study 
period 
 
2001-2003 2011-2012 1991-1996 2015-2017 
Study 
duration 
 
2 years 1 year 6 years 2 years 
Study 
design 
 
Prospective 
study 
Prospective 
study 
Prospective 
study 
Prospective case- 
control study 
Population  South India South India North India India, Bhutan, 
Bangladesh 
Age 
(mean ± 
SD) years 
37.06 ± 
30.12 
NA 34.5 44.4 ± 14.6 
M : F 0.87 : 1 1.5 : 1 1.47 : 1 0.41 : 1 
CADR(n) SJS/TEN - 
17 
SJS/TEN - 17 SJS/TEN - 57 SJS/TEN - 12 
DRESS - 0 DRESS - 7 DRESS - 0 DRESS - 7 
AGEP - 2 AGEP - 1 AGEP - 0 AGEP - 1 
Erythro - 3 Erythro - 2 Erythro - 9 Erythro - 1 
MPE - 11 MPE - 8 MPE - 173 MPE - 22 
EMM - 6 EMM - 3 EMM - 22 EMM - 4 
FDE - 28 FDE - 4 FDE - 150 FDE - 1 
 
Erythro – drug induced erythroderma 
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In these studies, other forms of CADRs such as urticaria and angioedema, lichenoid drug eruption and 
photosensitive reactions were also included. The type of CADRs included in each study is enclosed 
(Annexures 8). 
1.1 Age : The mean age of the patients recruited in our study was 44.4 ± 14.6 years, which was similar 
to other studies on cutaneous adverse drug reactions (91,92). In this cohort, 46% of the patients 
belonged to the age group of 40-60 years, which was in concordance with data published in 
previous studies (92–94). This trend could be due to the higher incidence of lifestyle associated 
diseases and subsequent polypharmacy in this age group, the increased risk of drug interactions and 
the altered metabolism and elimination of drugs from the body. However, there are Indian studies 
which have reported cutaneous drug reactions to be more common below 40 years of age (7,91). 
This has been attributed to the increased consumption of antibiotics in the younger age group. In 
our study group, 40% of patients were between the ages of 18 and 40 years (fig 5). 
 
1.2 Gender - There was a significant female preponderance in our study with a male : female  ratio of 
0.41:1 (fig 6). Many previous studies have shown a higher female : male ratio among patients with 
cutaneous adverse reactions (4,91,93). We also analysed the gender breakdown among the main 
groups of CADRs – MPE, SCARs, EMM and FDE – and found that the majority of the patients 
with MPE and SCARs were female (fig 7). This is contrary to the data published by 
Sasidharanpillai et al, which showed a male predominance in all SCARs except DRESS (94). The 
gender disparity in our study could reflect a complex interplay of socio-economic and cultural 
issues which affects the health-seeking behaviour in our population. For instance, women may 
consume more medications over the counter than men, resulting in higher incidence of drug 
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reactions (4). Also, men, being the primary wage earners in the family, may not seek treatment for 
non-severe drug reactions. The perception of illness may also be different between the genders. 
 
1.3 Day of presentation - More than half (58%) of the patients presented early in the course of the 
disease, i.e, within 5 days of onset of symptoms (fig 11). Only 15% patients (n=7) presented after 
more than 10 days of onset of symptoms. Three out of these seven patients (42.8%) had sought 
treatment elsewhere prior to this presentation. Among the male patients, approximately 94% sought 
medical attention within 10 days of onset of complaints whereas among the female patients, this 
percentage was lower (81%). This implies that a larger proportion of female patients sought medical 
attention later than their male counterparts.  
 
1.4  Latent period – The mean latent period for the DRESS patients in this study was markedly longer 
(16.1 ± 10.3 days) than MPE (8.4 ± 7.2 days). However, this difference was not statistically 
significant (p value 0.1032). Nevertheless, this is consistent with the observation that DRESS 
manifests 3-8 weeks after the ingestion of the offending drug. It is also noteworthy that despite the 
low sample size, the AGEP and FDE patients reported a mean latent period of 1 day, which 
conforms with data from literature (15) (table 5). 
 
2. DRUG DETAILS : 
The Naranjo Adverse Drug Reaction Probability Scale (Annexure 5) was used to assess causality of 
CADRs. Antiepileptic drugs were the commonest group of offending drugs (35.4%) among our patient 
population (fig 12). This was similar to the results of previous reports (5,44,51). Carbamazepine was 
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the most frequently encountered drug (20.83%, n=10), closely followed by phenytoin (18.75%, n=9). 
Levetiracetam, phenobarbitone and valproate were also reported to a lesser extent. Approximately 19% 
patients reported various antibiotics as the suspected drug. The most common antibiotics were beta 
lactams (penicillins, carbapenems and cephalosporins). This data conforms with findings from past 
studies (95,96).  
An interesting observation which emerged in this study was that antiepileptic agents were implicated as 
causative agents in 47.6% SCARs whereas antibiotics were the common culprit drug group (27.3%) 
among MPE. A study from Eastern India has made similar observations with antiepileptic drugs. In this 
study, 59% CADRs secondary to antiepileptic agents were SCARs (97).  
 
The other drugs identified in our study were proton pump inhibitors such as pantoprazole, diuretics 
such as hydralazine, torsemide and sulfa drugs (sulfasalazine, dapsone). Traditional or alternative 
medicine may also contribute to CADRs in our country (98). Among our study population, there was a 
maculopapular exanthema which was suspected to be secondary to siddha treatment.  
Literature shows anti-retroviral drugs and anti-tuberculous drugs as common causes of CADRs (99–
101). But these groups of drugs were under-reported in our cohort as patients with confirmed diagnosis 
of tuberculosis and HIV were excluded from our study due to the implicated role of serum granulysin 
in these chronic infections (102–104). 
 
One of our patients had maculopapular skin lesions strictly confined to the exposed areas of the face 
and upper limbs (clinical photograph – l,m). The suspected culprit drug was chlorpromazine, which is 
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a well recognised phototoxic and photoallergic drug (105,106). Chlorpromazine is known to cause 
severe persistent photosensitivity even after cessation of exposure to the drug (107). 
 
A maculopapular rash secondary to rabies vaccine/anti-rabies immunoglobulin was seen in one of our 
patients. Another patient who had been treated with carbamazepine and rituximab for neuromyelitis 
optica spectrum developed SJS. (108). This patient was also on carbamazepine for three weeks 
preceding the onset of symptoms and it may have been the culprit drug. However, the possibility of a 
Rituximab induced SJS could not be excluded (Naranjo causality score - 2). Rituximab induced 
Stevens-Johnson syndrome was first reported in 2002 by Lowndes et al (109). This diagnosis was later 
challenged by Henning and Firoz (108). 
 Five patients in the cohort had a past history of drug allergy. Pichler et al has reported a higher 
incidence of DRESS in patients with a past history of drug reactions(110), but this was not seen among 
our patient population. 
 
3. CLINICAL FEATURES : 
Cutaneous adverse drug reactions can have varied manifestations. The most common symptoms at 
presentation in our study were fever with mucocutaneous involvement (fig 9). Previous studies have 
established facial oedema as a hallmark in patients with DRESS syndrome and other SCARs 
(1,94,111). Among the DRESS patients in our study, the frequency of facial oedema was slightly 
higher (33.3%) than what has been previously described by Husain et al, i.e, 25% (112). However, this 
difference was not statistically significant. In our study, facial oedema was present in 28.57% of 
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SCARs and 22.7% of MPE (p value - 0.929) (table 6). Thus, facial oedema, which has heretofore been 
described as a classical feature of DRESS syndrome and other SCARs, may also be seen in non-severe 
CADRs. Blanching erythema, purpuric or atypical target lesions, erosions, erythematous papules and 
desquamation were the other facial features seen in our patients. 
 
4. SYSTEMIC MANIFESTATIONS :  
The most common systemic manifestation in our population was haematological abnormalities like 
lymphocytopenia followed by peripheral eosinophilia. Systemic features were more common among 
patients with SCARs. The laboratory parameters of our patients are compared with patients from other 
Indian studies in table 14. 
Table 14 - Comparison of laboratory parameters of patients with CADRs in different studies 
 
Parameter 
 
Pudukadan et 
al (31) 
Sasidharanpillai 
et al (34) 
Sharma VK et 
al (35) 
Present study 
Peripheral 
eosinophilia 
 
42.2% (n=38) DRESS – 100% 
 
NA SCARs – 35% 
 
MPE – 36.4% 
 
SJS/TEN – 
29.4% 
 
Erythroderma – 
50 % 
 
MPE, EMM, 
AGEP - 0 % 
Abnormal 
LFT 
Severe CADR 
– 88.9% 
 
Non severe 
CADR – 
11.11% 
DRESS – 100% 
 
NA MPE – 4.5% 
 
SCARs – 33.3% SJS/TEN – 
35.2% 
 
MPE – 12.5% 
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EMM – 33% 
 
Erythroderma, 
AGEP - 0 % 
Most 
common 
drugs 
 
Cotrimoxazole 
Dapsone 
 
Phenytoin 
Carbamazepine 
 
Cotrimoxazole 
Phenytoin 
 
Carbamazepine 
Phenytoin 
 
4.1 Lymphadenopathy - Lymphadenopathy was seen among 13.6% patients with MPE and 19% 
patients with SCARs (p value - 0.698). Among the patients with DRESS, 33.3% had enlarged 
nodes, a figure much lower than that reported in previous studies (44,52).  
 
4.2 Hepatic dysfunction – Transaminitis was present in 33.3% of patients with SCARs as compared to 
4.5% MPE. Thus, hepatic involvement was significantly more common in SCARs than MPE (p 
value – 0.021).  
 
4.3 Pulmonary involvement - Cough, dyspnea and chest radiograph changes suggestive of pulmonary 
involvement were noted in 9 out of the 48 patients (18.75%). Of these, 5 patients (55.5%) were 
SJS/TEN patients. One patient had erythema multiforme major. The other 3 patients had MPE. The 
most common lung findings noted were pulmonary infiltrates (55.5%, n=5) suggestive of interstitial 
pneumonitis. The incidence of pulmonary involvement in SCARs was higher than in MPE, but not 
statistically significant (p value – 0.098). Bronchiolitis obliterans, eosinophilic pneumonia, 
vasculitis and alveolar injury are the other drug induced pulmonary changes that have been reported 
in the past (113,114). However, none of these changes were observed in this cohort. It is also to be 
noted that 41.6% (n=5/12) of SJS/TEN patients had some form of pulmonary involvement.  
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4.4 Renal involvement – Severe cutaneous adverse reactions are associated with renal changes such as 
glomerulonephritis, late hypokalemia (36), interstitial nephritis (12), tubular necrosis (34) and acute 
renal failure (115). In our study, raised creatinine was seen in 6 patients, with equal number of 
patients in the MPE and SCARs group (p value – 0.345) (table 11). We noted that 25% of our 
SJS/TEN patients had abnormal renal parameters, similar to the data published in previous studies 
(36). Urine eosinophils was present only in 3 patients, all of whom had MPE. However, the 
specificity of urine eosinophil count for detection of interstitial nephritis is low (116).  
 
4.5 Cardiovascular involvement – Features suggestive of carditis were seen in one patient with 
DRESS (n=1/7, 14.3%). Kardaun et al reported a 13% incidence of complications in the heart or 
muscles in their landmark study on DRESS patients (44). Ampicillin, aromatic anticonvulsants and 
allopurinol have been most commonly associated with carditis in DRESS (117). In our patient, 
phenobarbitone was the suspected drug. 
 
4.6 Haematological abnormalities – Haematological abnormalities were fairly common among 
patients with all types of CADRs (table 11). 
a) Lymphocytopenia - The most common changes seen were lymphocytopenia, which was 
present in 68% of the total number of patients, 59% MPE and 80% SCARs (p value – 0.232). 
Lymphocytosis was not seen in any of our patients. Kardaun et al reported lymphocytosis 
and lymphopenia among 52% and 5% DRESS patients respectively.  
b) Thrombocytopenia– this finding was far more common among SCARs than MPE (28.6% 
vs 9%). However, this difference was not statistically significant (p value – 0.132).  
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c) Eosinophilia– Peripheral eosinophilia has traditionally been considered as an important 
diagnostic clue for drug induced aetiology.  In this cohort, 36.4% patients with MPE and 
35% of patients with SCARs had eosinophilia (p value > 0.99) (fig 18), which was lower 
than the figures noted in previous studies (31,34,39). It is also to be noted that contrary to 
popular belief, only a third of the patients with CADRs might have peripheral eosinophilia. 
Hence, the absence of peripheral eosinophilia may not rule out a drug induced etiology (8). 
This data also confirms the hypothesis that peripheral eosinophilia is associated with diffuse 
cutaneous reactions like MPE and SCARs as previously reported (118), regardless of the 
specific morphology or systemic involvement. 
 
Two important subsets of our patient population were SJS/TEN and DRESS cases. A comparison of 
the clinical profile of SJS/TEN patients in our study and few other studies in literature are enumerated 
below in table 15. 
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Table 15 – Comparison of clinical parameters of SJS/TEN patients in different studies 
 
Parameter 
Wang L et al 
(119) 
Chantaphaku
l 
et al (120) 
Wong et al 
(121) 
Sharma et al 
(122) 
Naveen et al 
(123) 
Present 
study 
Country  China  Thailand  Australia  India India India 
Study 
period 
2006 - 2015 Published in 
2015 
1985 - 1997 2003 - 2006 Published in 
2013 
2015 - 2017 
Study 
duration  
10 years 5 years 12 years 4 years 5 years 2 years 
Study 
design 
Retrospectiv
e  
Retrospectiv
e  
Retrospectiv
e   
Retrospectiv
e 
Retrospectiv
e  
Prospective  
Subjects  
(n) 
88 43 17 30 22 12 
M : F 0.83 : 1 1.4 : 1 1.83 : 1 0.76 : 1 1.75 : 1 0.16 : 1 
Age 
(mean ± 
SD) 
years 
45 ± 18  49.5 (range 
20-85) 
61.5 (range 
23–83) 
22.3 ± 15.4 32.3 (range 
1- 65) 
44.4 ± 14.6 
Common 
drugs 
Antibiotics 
 
Allopurinol Antibiotics  AED AED AED 
Visceral 
involveme
nt 
47.7% 48.8% NA NA NA 66.67% 
AED – antiepileptic drugs 
All the studies mentioned in the comparison were retrospective studies. The mean age of our study 
patients (44.4 ± 14.6 years) was similar to that of the other studies, except 2 studies which included 
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pediatric patients. The most commonly implicated drugs in all the Indian studies were antiepileptic 
agents. Systemic involvement was higher (66.67%) among the patients included in our study. 
 
A similar comparison of DRESS patients in our study with other studies is shown in table 16. 
Table 16 - Comparison of demographic and clinical profile of patients with DRESS in different studies 
 
Parameter Kardaun et al 
(44) 
Lee JY et al 
(124) 
Eshki et al 
(45) 
Present study 
 
 
Country 
 
Europe  Korea France  India 
Study period 
 
2003 - 2009 2006 - 2015 1995 - 2006 2015 - 2017 
Study duration 
 
7 years 10 years 12 years 2 years 
Study design 
 
Prospective 
study 
Retrospective 
study 
Retrospective 
study 
Prospective 
case control 
study 
Subjects  
 
DRESS 
(n = 117) 
DRESS (n=25) Severe 
DRESS  
(n = 15) 
DRESS (n=7) 
M : F 
 
0.80 : 1 0.78 : 1 NA 0.75 : 1 
Drugs implicated 
 
Carbamazepine, 
allopurinol 
Carbamazepine, 
allopurinol 
Allopurinol, 
minocycline 
carbamazepine 
Facial oedema 
 
76% 28% NA 28.6% 
Mucosal lesions 56% 
 
20% NA 42.9% 
Lymph node 
enlargement 
 
54% 64% NA 42.9% 
Abnormal LFT 
 
75% 80% 46.7% 57.1% 
Abnormal RFT 
 
37% 28% 33.3% 0% 
Pulmonary 
involvement 
32% 20% 66.7% 0% 
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Peripheral 
eosinophilia 
95% 80% NA 71.4%% 
Lymphocytopenia 
 
5% NA NA 14.3% 
Lymphocytosis 
 
52% NA NA 0% 
Thrombocytopenia 
 
 
7% 40% NA 28.6% 
Thrombocytosis 19% NA NA 
 
0% 
 
The total number of DRESS patients in our study was lesser than the other studies in this comparison. 
There was a female preponderance in our study group similar to other studies. The most commonly 
implicated drugs were aromatic anticonvulsants like carbamazepine. Mucosal involvement was seen in 
42.9% of our patients. The incidence of facial oedema was lesser in this study as compared to the data 
published by Kardaun et al. In contrast, lymphocytopenia and thrombocytopenia were more commonly 
seen.  
 
5. HISTOPATHOLOGY  : 
Few characteristic histopathological features were seen in drug induced reactions. 
5.1 Dermal eosinophilia - Of the 24 patients who underwent histopathological analysis, dermal 
eosinophilic infiltrate was the most commonly encountered finding. In the study by Weinborn et al, the 
prevalence of dermal eosinophilia was 61% as opposed to 83.3% in our study (63). This confirms that 
peripheral eosinophilia does not necessarily correlate with dermal eosinophilia (118) as already 
reported in previous studies. The incidence of dermal eosinophilia was comparable among the MPE 
and SCARs groups in this study (p value > 0.99). Two out of the 3 DRESS patients (66.67%) who 
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underwent histopathological analysis showed dermal eosinophilic infiltrate, similar to the data 
published earlier (125). In this study, Weinborn et al also reported basal cell vacoulization in 50% 
cases of DRESS. 
 
5.2 Necrotic keratinocytes - In our study, necrotic keratinocytes were seen in 100% patients with 
SCARs whereas lymphocytic exocytosis was seen in 90% patients with SCARs. This is in conformity 
with the observations of  Weinborn et al (125). Both necrotic keratinocytes and lymphocytic exocytosis 
were significantly more common in SCARs than MPE (p value – 0.01 and 0.045 respectively). 
Thus, interface vacoulization, lymphocytic exocytosis, dyskeratosis and spongiosis were all more 
common among the SCARs than in MPE as shown previously by Chi et al (65). 
The findings in our study also confirms that there are no characteristic histopathological features in 
MPE(63). The usual findings noted are spongiosis, dermal oedema and a perivascular infiltrate.  
 
6. ROLE OF SERUM GRANULYSIN : 
Serum granulysin levels of different CADRs were measured and compared. The median granulysin 
concentration in patients with SJS/TEN in our study was lower than that reported by Fujita et al (86). 
Among the DRESS patients in our study, the median granulysin level was 0.24 ng/ml, which was lower 
than that detected by Saito et al. The test kit used was different, hence, a direct comparison cannot be 
done. 
The study characteristics of our study are compared with existing literature in table 17. 
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Table 17 - Comparison of study characteristics of different studies on serum granulysin in CADRs 
 
 Present study Fujita et al (86) Saito et al (47) 
Country India Japan Japan  
Study period November 2015 – 
May 2017 
NA (published in 2011) NA (published in 
2012) 
Study duration 19 months NA NA 
Study design Single center, 
case control study 
Multi center, case-
control study 
Multi center, case-
control study 
Number of 
patients (cases) 
n = 21 SCARs + 
22 MPE + 4 
EMM+ 1 FDE 
n = 5 SJS/TEN n = 15 DRESS  
Day of inclusion  At first 
presentation 
(ranged between 
day 1 to day 30) 
2-4 days prior to 
epidermal detachment 
Serial monitoring 
done – day 1-10, 
day 11-20, day 21 
and above 
Controls  20 healthy 
controls 
24 patients with ODSRs 
(specific type NA), 31 
healthy controls 
24 patients with 
MPE/ EMM, 31 
healthy controls 
Type of test ELISA Rapid 
immunochromatographic 
strip test and ELISA 
ELISA 
Range of 
detection of serum 
granulysin 
0.03 ng/ml to 4 
ng/ml 
NA (granulysin titer 
ranged between 2.7 
ng/ml – 52.1 ng/ml) 
NA (granulysin 
titer ranged 
between 1.6 ± 0.6 
ng/ml to 21.9 ± 12 
ng/ml 
Test kit used Biovendor  Recombinant granulysin, MBL, Nagoya, 
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RD191327200R 
Human 
Granulysin, 
Czech Republic 
R&D Systems, 
Minneapolis, MN 
Japan 
 
 
Existing literature shows that granulysin is highly expressed in the blister fluid seen in SJS/TEN (30). 
Further studies reported serum granulysin to be elevated in the early stages of SJS/TEN (with rapidly 
falling titers within few days of epidermal detachment) as compared to ODSRs. But this finding was 
not reproduced in our study. Among the 12 patients with SJS/TEN, serum granulysin > 4 ng/ml (upper 
limit of detection) was only seen in one patient, which remained persistently high on day 3. Most of our 
patients had epidermal detachment at initial presentation and hence, serial measurement of granulysin 
was not performed for all patients with SJS/TEN.  
In contrast, studies have shown a prolonged elevation of serum granulysin in DRESS (47). This was 
also not seen among our patients. In our study, the granulysin titers were comparable among the MPE, 
SCARs, EMM, drug induced erythroderma and healthy controls. We cannot comment on serum 
granulysin in bullous FDE and AGEP due to the low sample size.  
 
6.1 Comparison of serum granulysin in SJS/TEN and EMM 
An interesting observation that emerged in our study was the difference in granulysin levels of 
SJS/TEN and EMM. It has also been established that there is a significant difference in the expression 
of granulysin in the tissue of patients with SJS/TEN and EMM (71). At the onset of the disease, both 
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erythema multiforme major and Stevens Johnson syndrome present with purpuric or target lesions, 
which may further progress to mucocutaneous erosions. However, EMM is self-limiting and 
symptomatically less severe as compared to SJS/TEN. In our study, we found that serum granulysin 
was significantly higher in SJS/TEN than EMM (p value – 0.042), and can therefore be used to 
distinguish between the two conditions.  
 
At the end of our study, we concluded that serum granulysin may not be uniformly raised in SCARs 
like SJS/TEN and DRESS as reported earlier. Further studies with larger sample size need to be done 
to reassess the role of granulysin in various CADRs. 
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CONCLUSION  
 
1. In this study, there were forty eight patients with various cutaneous adverse reactions including 
maculopapular exanthema (n = 22), erythema multiforme major (n = 4), fixed drug eruption (n = 
1), SJS/TEN (n = 12), DRESS (n = 7), drug induced erythroderma (n = 1) and AGEP (n = 1). 
2. The mean age was 44.4 ± 14.6 years with the most common age group affected being 40-60 
years (n=22/48, 46%).  
3. There was a strong female preponderance (M:F 0.41:1) with 68.18% MPE patients (n=15/22) 
and 76.19% SCARs patients (n=16/21) being women. 
4. The most common drug group implicated among all the CADRs in our study was antiepileptic 
drugs (n=17/48, 35.4%). Carbamazepine was the most commonly reported drug (n=10/48, 
20.83%).  
5. In our study, antiepileptic drugs were the most commonly implicated drugs in SCARs (n=10/21, 
47.6%) and antibiotics were the most commonly implicated drugs in MPE (n=6/22, 27.3%). 
6. The prevalence of facial oedema among patients with MPE and SCARs was comparable 
(n=5/22, 22.7% vs n=6/21, 28.57%, p – 0.929).  
7. Palmoplantar involvement was more common in patients with SCARs (n=9/21, 42.85%) than in 
patients with MPE (n=3/22, 13.6%). 
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8. There was no significant difference in the frequency of peripheral eosinophilia among MPE and 
SCARs (36.4% vs 35%, p > 0.99). 
9. Peripheral eosinophilia was found only in about one third of the patients with CADRs (n=15/48, 
31.25%) and thus, the absence of peripheral eosinophilia may not rule out drug induced 
aetiology. 
10. Transaminitis was significantly more common in SCARs than MPE with (n=7/21, 33.3% vs 
n=1/22, 4.5%, p value 0.021). 
11.  Lymphocytopenia (80% SCARs and 59.1% MPE) and thrombocytopenia (28.6% SCARs and 
9.1% MPE) were seen more in patients with SCARs in comparison to those with MPE. 
However, this was not statistically significant (p value 0.232, 0.132 respectively). 
12. The most frequently encountered histopathological feature in CADRs was dermal eosinophils 
(n=20/24, 83.3%).  
13. The occurrence of spongiosis (n=7/10, 70% SCARs and n=7/12, 58.3% MPE) and dermal 
eosinophilia (n=9/10, 90% SCARs and n=10/12, 83.3% MPE) among SCARs and MPE were 
comparable (p – 0.321, > 0.99 respectively).  
14. Necrotic keratinocytes on histopathology was seen in all the cases of SCARs (n=10/10, 100%). 
15. Necrotic keratinocytes were significantly more common in the histopathology of SCARs 
(n=10/10, 100%) as compared to MPE (n=5/12, 41.6%) (p – 0.01). 
16. Lymphocytic exocytosis was more commonly seen in SCARs than MPE (n=9/10, 90% vs 
n=6/12, 50%, p – 0.045). 
 
109 
 
17. There was no significant difference in serum granulysin between patients with maculopapular 
exanthema (median – 0.15 ng/ml), severe cutaneous adverse reactions (median – 0.26 ng/ml) or 
healthy controls (0.27 ng/ml). Thus, serum granulysin may not be specific for SJS/TEN as 
thought previously. 
18. There was no correlation between serum granulysin and the severity of the cutaneous adverse 
drug reaction.  
19. Granulysin titer was significantly higher in patients with SJS/TEN than in patients with 
erythema multiforme major (0.275 ng/ml vs 0.125 ng/ml, p value – 0.042). 
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LIMITATIONS  
 
1. In patients with established epidermal detachment, serial measurement of granulysin was not 
done. 
2. The range of detection of serum granulysin was lower in our test kit than that used in other 
studies. 
 
 
 
 
 
RECOMMENDATION  
 
Multi-center studies with larger number of patients should be conducted to assess the levels of 
granulysin in CADRs and its correlation with the severity of the rash. 
Serum granulysin should be correlated with the granulysin expression in skin in patients to ascertain 
the pathogenetic role of granulysin in cutaneous adverse drug reactions. 
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ANNEXURE 2 - INFORMATION SHEET 
 
Study Title: A pilot study of serum granulysin in drug induced exanthems and severe cutaneous 
adverse reactions (SCARs) 
 
     CHRISTIAN MEDICAL COLLEGE, VELLORE - DEPARTMENT OF DERMATOLOGY 
                                                         
 
Explanation of the purpose of research? 
Drug eruptions are very common and usually occur within a few weeks of starting new medications. 
While majority of these are harmless and resolve in a few weeks with supportive management, a small 
proportion can evolve into life threatening disease. In the initial stages, all drug eruptions appear 
similar. Identifying the patients who are at risk of progressing into a severe disease early would help 
the doctor to manage the patient aggressively with systemic and topical treatment in an in-patient set 
up, thus potentially reducing the death rate. Granulysin is a molecule which was identified as a key 
mediator responsible for the skin manifestations in severe drug eruptions. It is increased in the blood in 
patients before the appearance of the rash. This study will help us to show the relationship between 
granulysin and the different types of drug eruptions. This may help us to recommend granulysin as a 
predictor of severe drug eruptions in patients who present early in the course of the illness.  
 
What will you have to do if you participate in his study?  
If you agree to participate in this study once you have been diagnosed to have drug eruptions, you will 
be requested to allow a doctor to take a detailed history and examination. You are also required to give 
blood sample for the measurement of serum granulysin. In case of worsening lesions, you will be 
requested to give a second blood sample. The detected serum granulysin level is then correlated with 
disease severity and compared with that of healthy individuals. 
 
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to withdraw 
permission to participate in this study. If you do so, this will not affect your usual treatment at this 
hospital in anyway. 
 
What will happen if you develop any study related injury? 
We do not expect any injury to happen to you but if you do develop any side effects or problems due to 
the study these will be treated at no cost to you. 
 
Will you have to pay for the blood test? 
The test serum granulysin concentration will be done for you free of cost. 
 
Will your personal details be kept confidential? 
 
130 
 
The results of this study will be published in a medical journal but you will not be identified by name 
in any publication or presentation of results. However your medical notes may be reviewed by people 
associated with the study without your additional permission should you decide to participate in this 
study. 
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ANNEXURE 3 - INFORMED CONSENT FORM  
 
 
Study Title: A pilot study of serum granulysin in drug induced exanthems and severe cutaneous 
adverse reactions (SCARs) 
 
Study Number: ____________ 
 
Subject’s Name: _________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ for the 
above study and have had the opportunity to ask questions. [  ] 
 
(ii)  I understand that my participation in the study is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected. [  ] 
 
(iii)  I understand that the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any further 
research that may be conducted in relation to it, even if I withdraw from the trial. I agree to this 
access. However, I understand that my identity will not be revealed in any information released 
to third parties or published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided such a use 
is only for scientific purpose(s). [  ] 
 
(v)  I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________         Signature:  
Or 
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Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature or thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
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ANNEXURE 4 - CLINICAL RESEARCH FORM 
 
A pilot study of serum granulysin in drug induced exanthems and severe cutaneous adverse  
reactions (SCARs) 
 
Date:                                                                                                               Serial no:  
Name:                                                  Hospital no:  
Age:                  
Sex:   Male / Female                   Occupation:  
Address:   
State:  
Contact number:  
Presenting complaints:  
Day since the onset of the first skin lesion -  
1. Duration of symptoms -  
 
Symptom  Yes  No  Duration   
Itching     
Burning sensation      
Conjunctival lesions    
Oral mucosal lesions    
 
Genital mucosal lesions    
 
Others      
 
2. Systemic complaints:  
Symptoms  Yes  No  Duration   
Fever      
Cough      
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Breathlessness      
Jaundice      
Arthralgia      
Swelling of face /hands 
and feet     
 
 
Drug/drugs implicated-  
Indication for the initiation of these new drug/drugs -   
Type of the implicated drug – anticonvulsants / antibiotics / analgesics / antiretroviral / 
antituberculous drugs 
 
Sl.no  Medication  Initiation date  
Date of 
stoppage  Duration  Half life  
      
      
      
      
 
 
Concurrent drugs:   
 
Serial number  Drug  Duration  Other 
comments  
    
    
    
 
 
Previous history of drug reaction: yes/no   
 
If yes, then details:  
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Serial 
no  Drug name  Type of reaction  
Date of 
previous 
reaction  
    
    
 
Drug timeline -  
Drug -5 -4 -3 -2 -1 Day 0 +1 +2 +3 
1.          
2.          
3.          
4.          
 
Is the patient on systemic steroids?    Yes / No 
If yes, duration : 
Indication : 
 
Other co-morbidities-   
 
Personal history:  
Alcohol, if yes: duration_______ (in years) and amount______ (in ml) 
 
Clinical Features:  
Fever:  
Heart rate:  
Respiratory rate:  
Blood pressure:   
Lymphadenopathy:  
 
Respiratory system:  
 
Gastrointestinal system:  
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Type of lesion: Blanching erythema / macular / papular / maculopapular / purpuric /   erythema 
multiforme-like (targetoid) / vesicles / pustules / bullae / erosions   
 
Body surface area:   
 
<10%     
10% -30%   
>30%   
 
Scaling  :  Yes / No  
 
Palms and soles  :  yes / no                       
If yes, describe :  
 
Face involvement : yes / no  
 If yes, describe :  
 
Mucosal involvement : yes / no  
If yes,describe  :  
 
Eyes   :  
 
Oral cavity  :  
 
Genitalia  :  
 
Nail changes   :  yes / no  
If yes, describe  :  
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Hair / scalp changes : yes / no If yes, 
describe  :  
 
Others  :  
 
Investigations   
 Day no. _ 
Haemoglobin  
Platelets  
Total counts   
Differential counts   
Total bilirubin   
Total protein  
Serum albumin  
SGOT   
SGPT  
Alkaline phosphatase    
Serum creatinine   
Urine for eosinophils   
Chest X ray findings   
HIV    
Serum granulysin  
 
Repeat granulysin  -    Yes/No 
If yes, value : 
OTHERS:   
 
Histopathology findings with date : 
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ANNEXURE  5 - NARANJO ADVERSE DRUG REACTION PROBABILITY 
SCALE 
 
 
 
Naranjo Adverse Drug Reaction Probability Scale  
  
 
       Question  Yes  No  Do Not 
Know  
Score  
1. Are there previous conclusive reports on this reaction?  +1  0  0    
2. Did the adverse event appear after the suspected drug was administered?  +2  ‐1  0    
3. Did the adverse reaction improve when the drug was discontinued or a 
specific antagonist was administered?  
+1  0  0    
4. Did the adverse event reappear when the drug was re‐administered?  +2  ‐1  0    
5. Are there alternative causes (other than the drug) that could on their own 
have caused the reaction?  
‐1  +2  0    
6. Did the reaction reappear when a placebo was given?  ‐1  +1  0    
7. Was the drug detected in blood (or other fluids) in concentrations known to 
be toxic?  
+1  0  0    
8. Was the reaction more severe when the dose was increased or less severe 
when the dose was decreased?  
+1  0  0    
9. Did the patient have a similar reaction to the same or similar drugs in any 
previous exposure?  
+1  0  0    
10. Was the adverse event confirmed by any objective evidence?  +1  0  0    
  
                                                                                                                                                TOTAL SCORE:  
  
  
Modified from:   Naranjo CA et al.  A method for estimating the probability of adverse drug reactions.  Clin  
Pharmacol Ther 1981; 30: 239­245.  
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ANNEXURE 6 - RegiSCAR criteria 
 
 
It comprises of the following essential criteria :  
 
1. Hospitalization  
2. Reaction suspected to be drug related  
3. Acute skin rash 
In addition, the patient has to have at least 3 of the following asterisked criteria. 
4. Fever more than 38°C *  
5. Enlarged lymph nodes at two or more sites*  
6. Involvement of at least one internal organ*  
7. Haematological abnormalities *  (leukocytosis, lymphocytosis, lymphocytopenia, eosinophilia or 
thrombocytopenia) 
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ANNEXURE  7 - AGEP VALIDATION SCORE BY THE EUROSCAR 
STUDY GROUP 
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ANNEXURE 8 – PROFILE OF CADR INCLUDED IN DIFFERENT 
STUDIES 
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Adapted from Sharma et al (7) 
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Adapted from sasidharanpillai et al (94) 
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ANNEXURE  9 - DATA SHEET 
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